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Heart	   hypertrophy:	   pathogenesis	   and	   new	   potential	   pharmacological	  
targets	  Cardiac	   hypertrophy	   is	   an	   adaptive	   response	   to	   pressure	   or	   volume	   stress,	  mutations	  of	   sarcomeric	   (or	  other)	  proteins,	  or	   loss	  of	   contractile	  mass	   from	  prior	   infarction.	   Hypertrophic	   growth	   accompanies	   many	   forms	   of	   heart	  diseases	   like	   ischemic	   disease,	   hypertension,	   heart	   failure,	   and	   valvular	  disease12.	   In	   these	   types	   of	   cardiac	   pathology,	   pressure	   overload–induced	  concentric	   hypertrophy	   is	   believed	   to	   have	   a	   compensatory	   function	   by	  diminishing	   wall	   stress	   and	   oxygen	   consumption.	   Moreover,	   ventricular	  hypertrophy	  is	  associated	  with	  significantly	  increased	  risk	  of	  heart	  failure	  and	  malignant	  arrhythmia34.	  Hypertrophic	   transformation	   of	   the	   heart	   is	   subdivided	   into	   3	   steps5:	   (1)	  developing	   hypertrophy,	   with	   load	   exceeds	   output,	   (2)	   compensatory	  hypertrophy,	   in	   which	   the	   workload/mass	   ratio	   is	   normalized	   and	   resting	  cardiac	   output	   is	   maintained,	   and	   (3)	   overt	   heart	   failure,	   with	   ventricular	  dilation	   and	   progressive	   declines	   in	   cardiac	   output	   despite	   continuous	  activation	  of	  the	  hypertrophic	  program6.	  The	  late-­‐phase	  “remodeling”	  process	  that	  leads	  to	  failure	  is	  associated	  with	  functional	  perturbations	  of	  cellular	  Ca2+	  homeostasis	  and	  ionic	  currents7,8,	  which	  contribute	  to	  an	  adverse	  prognosis	  by	  predisposing	  to	  ventricular	  dysfunction	  and	  malignant	  arrhythmia.	  Significant	  morphological	   changes	   include	   increased	   rates	   of	   apoptosis9,	   fibrosis,	   and	  chamber	  dilation.	  The	   cellular	   hypertrophic	   response	   is	   an	   important	   adaptive	   process	   in	   the	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cardiomyocites	   in	   response	   to	   various	   extracellular	   stimuli	   like	   mechanical	  stress,	   cytokines,	   and	   growth	   factors,	   moreover	   it	   is	   characterized	   by	   an	  increase	   in	  cell	  volume,	   the	  assembly	  of	  contractile	  proteins	   into	  reorganized	  sarcomeric	  units.	  At	  the	  molecular	  level,	  these	  changes	  in	  cellular	  phenotype	  are	  accompanied	  by	  reinduction	   of	   the	   so-­‐called	   fetal	   gene	   program,	   because	   patterns	   of	   gene	  expression	   mimic	   those	   seen	   during	   embryonic	   development	   like	   the	  reactivation	   of	   atrial	   natriuretic	   factor	   (ANF)	   and	   brain	   natriuretic	   peptide	  (BNP),	   for	   this	   reason,	   both	   peptides	   are	   used	   as	   prognostic	   and	   diagnostic	  markers	   in	   many	   cardiovascular	   abnormalities	   such	   as	   hypertension,	   heart	  failure,	   left	   ventricular	   diastolic	   dysfunction,	   valvular	   stenosis	   and	   coronary	  artery	  disease10.	  During	   the	   heart	   hypertrophy	   development	  we	   can	   distinguish	   two	   different	  phenotypes:	   (1)	   concentric	   hypertrophy	   due	   to	   pressure	   overload,	  characterized	   by	   parallel	   addition	   of	   sarcomeres	   and	   lateral	   growth	   of	  individual	   cardiomyocytes,	   and	   (2)	   eccentric	   hypertrophy	   due	   to	   volume	  overload	  or	  prior	  infarction,	  characterized	  by	  addition	  of	  sarcomeres	  in	  series	  and	  longitudinal	  cell	  growth11.	  	  Experimental	   evedence	   suggest	   that	   the	   renin–angiotensin	   system	   (RAS)	   and	  its	  effector	  peptide,	  angiotensin	  II	  (Ang	  II),	  are	  involved	  in	  the	  pathophysiology	  of	   cardiac	   hypertrophy	   and	   failure.	   All	   the	   components	   required	   for	   Ang	   II	  production	  are	  present	  in	  the	  heart,	  and	  cardiac	  Ang	  II	  formation	  appears	  to	  be	  regulated	   independent	   from	   the	   circulating	   RAS.	   In	   animal	   models	   and	   in	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Figure1:	   Role	   of	   NADPH	   oxidase	   in	   the	   production	   of	   reactive	   oxygen	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cytosol,	   whereas	   p22phox	   and	   gp91phox	   are	   in	   the	   membrane,	   where	   they	  occur	   as	   a	   heterodimeric	   flavoprotein,	   cytochrome	   b558.	   On	   stimulation,	  p47phox	  becomes	  phosphorylated	  and	  the	  cytosolic	  subunits	   form	  a	  complex	  that	  translocates	  to	  the	  membrane,	  where	  it	  associates	  with	  cyto-­‐chrome	  b558	  to	  assemble	  the	  active	  oxidase,	  which	  transfers	  electrons	  from	  the	  substrate	  to	  O2,	   forming	   .O2-­‐	   14. A	   second	   important	   event	   required	   for	   NADPH	   oxidase	  activity	   is	   Rac	   activation	   and	   membrane	   translocation.	   The	   mechanisms	   by	  which	  Rac	  regulates	  the	  NADPH	  oxidase	  are	  incompletely	  understood.	  In	  cell-­‐free	  oxidase	  reconstitution	  assays,	  the	  Rac-­‐GTP	  active	  form	  is	  essential	  for	  high	  level	  superoxide	  production15,16.	  Rac-­‐GTP	  binds	  the	  N-­‐terminal	  TPR	  (tetratrico	  repeat)	   region	   of	   p67phox	   and	   may	   also	   interact	   directly	   with	   the	  flavocytochrome	  in	  the	  assembled	  oxidase	  complex17–22.	  Seven	   isoforms	  of	  NADPH	  oxidase	  have	  been	  described	   in	  mammals.	  Each	  of	  these	   isoforms	  comprises	  a	   core	   catalytic	   subunit,	   the	  NADPH	  oxidase	   (NOX)	  and	  dual	  oxidase	   (DUOX)	   subunits,	   and	  up	   to	   five	   regulatory	   subunits.	  These	  regulatory	  subunits	  have	  important	  roles	  in:	  maturation	  and	  expression	  of	  the	  NOX	   and	   DUOX	   subunits	   in	   biological	   membranes,	   (ie,	   p22phox,	   DUOX	  activator	   1,	   and	  DUOX	   activator	   2),	   in	   enzyme	   activation	   (p67phox	   and	  NOX	  activator	   1),	   and	   in	   spatial	   organization	   of	   the	   various	   components	   of	   the	  enzyme	  complex	  (p47phox,	  NOX	  organizer	  1,	  and	  p40phox).	  	  The	   biological	   roles	   of	   NADPH	   oxidase	   make	   it	   an	   interesting	   therapeutic	  target,	   because	   the	   ROS-­‐generating	   activity	   of	   vascular	   smooth	   muscle	   cells	  and	  endothelial	  NADPH	  oxidases	  is	  increased	  by	  stimuli	  such	  as	  angiotensin	  II,	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tumor	   necrosis	   factor-­‐α,	   growth	   factors	   and	   cyclical	   load.	   Vascular	   NADPH	  oxidases	  are	  implicated	  in	  the	  development	  of	  angiotensinII–induced	  vascular	  smooth	  muscle	   cells	   hypertrophy,	   hypertension,	   endothelial	   dysfunction,	   and	  atherosclerosis.	   However,	   further	   investigations	   are	   needed	   to	   clarify	   the	  different	   roles	   of	   the	   NADPH	   oxidase	   isoforms	   and	   their	   participation	   in	  signaling	   pathways,	   in	   addition	   to	   the	   requirement	   for	   developing	   isoform-­‐specific	  inhibitors.	  The	   oxidative	   stress	   damages	   the	   proteins,	   lipids	   and	   DNA,	   causing	   cellular	  dysfunction23.	   In	  particular,	   an	   excess	  of	  O2.–	  may	  decrease	  nitric	   oxide	   (NO)	  availability,	  leading	  to	  endothelial	  dysfunction	  and	  a	  decrease	  in	  endothelium-­‐dependent	  vasodilation24.	  Additionally,	  oxidative	  modification	  of	  proteins	  may	  result	   in	   the	   formation	   of	   nitrotyrosine,	   which	   represents	   a	   powerful	   and	  autonomous	  marker	  of	  cardiovascular	  diseases.	  Furthermore,	  O2.–	   is	   implicated	   in	   the	   generation	  of	   oxidized	  LDL	   (oxLDL),	   a	  key	  initiator	  of	  atherosclerosis25.	  Rac1	  has	  been	  reported	  to	  be	  a	  key	  regulator	  of	  oxidative	  stress	  through	  its	  co-­‐regulatory	   effects	   on	   both	   NO	   synthase	   and	   NOX,	   moreover	   Rac1	   performs	  many	   important	   biological	   functions	   in	   cells,	   but	   perhaps	   the	   most	   unique	  function	   is	   its	   ability	   to	   bind	   and	   activate	   the	   NOX	   complex.	   Upon	   enzyme	  activation,	   translocation	   as	  well	   as	   assembly	   of	   the	   cytosolic	   subunits	   to	   the	  membrane	  subunits	  take	  place.	  In	  the	  activated	  enzyme	  complex,	  the	  catalytic	  subunit	  acts	  as	  an	  electron	  transport	  system	  that	  utilizes	  NADPH	  as	  an	  electron	  donor	   to	   transfer	   electrons	   to	  molecular	   oxygen,	   leading	   to	   the	   formation	   of	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O2.–	  26,27.	  	  In	  various	   studies	   the,	  upregulation	  of	  Rac1	  and	  p47phox	  membrane	  protein	  expression	   as	   well	   as	   increased	   Rac1-­‐GTPase	   activity	   may	   resemble	   the	  underlying	   mechanisms	   for	   increased	   oxidase	   activity,	   in	   particular,	   Rac1-­‐GTPase	   activation	   seems	   to	   play	   a	   main	   role	   in	   the	   initiation	   of	   cardiac	  hypertrophy	   linking	   NOX-­‐related	   ROS	   production	   to	   the	   hypertrophic	  signalling	  cascade.	  
	  
BNP	  and	  ANF:	  biomarkers	  for	  heart	  development	  and	  disease	  The	   heart	   of	   mammals	   expresses	   atrial	   natriuretic	   factor	   (ANF,	   ANP,	   a-­‐type	  natriuretic	   peptide)	   and	   brain	   natriuretic	   peptide	   (BNP,	   b-­‐type	   natriuretic	  peptide).	   Both	   proteins	   and	   their	   encoding	   genes	   have	   been	   studied	  extensively28,29	   for	   their	   various	   physiological	   functions	   and	   expression	   in	  different	  organs.	  	  Their	   main	   effects	   are	   to	   lower	   blood	   volume,	   reducing	   cardiac	   output	   and	  systemic	  blood	  pressure.	  	  Ventricular	   expression	  of	   the	   genes	   for	  ANF	  and	  BNP	   is	  downregulated	   after	  birth,	   while	   their	   levels	   significantly	   increase	   during	   heart	   hypertrophy	   and	  heart	  failure.	  	  ANF	  was	   the	   first	   natriuretic	   peptide	   to	   be	   identified,	  when	   it	  was	   shown	   to	  increase	   natriuresis,	   diuresis	   and	   vasodilation30,	   moreover	   the	   spectrum	   of	  action	  was	  not	  limited	  to	  cardiovascular	  and	  renal	  systems.	  Receptors	  for	  ANF	  were	   identified	   in	   different	   organs	   including	   the	   kidney,	   lung,	   liver,	   adrenal	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cortex,	  and	  the	  small	  intestines,	  where	  it	  could	  regulate	  salt	  and	  water	  balance	  as	  well31,	  also	  ANF	  receptors31	  as	  well	  as	  bioactive	  peptide	  were	  also	  found	  in	  the	  brain32,33,34,	  where	  contains	  another	  NP,	  therefore	  called	  BNP35.	  In	   the	  brain	  NPs	   inhibit	   the	   release	  of	   adrenocorticotropic	  hormone,	   thereby	  decreasing	   aldosterone	   release	   and	   enhancing	   natriuresis.	   Furthermore,	   the	  ANF-­‐ergic	   neurons	   inhibit	   arginine	   vasopressin	   release	   leading	   to	   diuresis36.	  Therefore,	   NPs	   expressed	   in	   the	   brain	   also	   serve	   to	  maintain	   optimal	   liquid	  homeostasis.	   Although	   BNP	  was	   isolated	   from	   the	   brain,	   it	   is	   predominantly	  expressed	   in	   the	   heart	   ventricles	   and	  mimics	   the	   pharmacological	   activity	   of	  ANF	  in	  regulation	  of	  blood	  pressure,	  ANF	  and	  BNP	  proteins	  showed	  a	  similar	  structure.	  ANF	  and	  BNP	  are	  stored	  in	  the	  same	  secretory	  granules	  in	  the	  atria	  therefore	  during	  cardiac	  cell	  stress,	  they	  are	  rapidly	  released	  from	  pre-­‐stored	  granules37,	  and	  their	  concentration	  in	  the	  blood	  is	  expected	  to	  rise	  simultaneously	  and	  to	  the	  same	  grade.	  Indeed,	   studies	   show	   synchronous	   elevation	   of	   plasma	   ANF	   and	   BNP	   during	  the	  time-­‐course	  of	  acute	  volume	  or	  pressure	  overload38,39	  as	  well	  as	  presence	  of	  both	  elevated	  ANF	  and	  BNP	  in	  chronic	  models	  of	  hypertension.	  The	   induction	  of	  NP	  levels	  and	  gene	  expression	  in	  response	  to	  heart	  diseases	  were	   performed	   both	   in	   short-­‐term	   experiments	   and	   in	   a	   long	   term	  experiments:	   Short-­‐term	   experiments	  were	   performed	  with	   isolated	   atria	   or	  ventricles	   to	   estimate	   secretion	   of	   NPs	   in	   minutes	   after	   stimulation,	   which	  showed	  that	  both	  ANF	  and	  BNP	  were	  acutely	  secreted	  with	  a	  peak	  at	  about	  20
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30	  min	  after	  atrial	  pacing40,41	  and	  after	  1–5	  min	  after	  ventricular	  stimulation42.	  These	  results	  indicate	  that	  atrial	  and	  ventricular	  myocytes	  rapidly	  respond	  to	  stress.	  In	  a	  long	  term	  experiments	  with	  chronic	  overload	  revealed	  some	  differences	  in	  atrial	  and	  ventricular	  secretion	  of	  the	  NPs:	  in	  spontaneously	  hypertensive	  rats	  (SHR)	   the	   secretion	   of	   ANF	   from	   the	   overloaded	   left	   ventricle	   was	  accompanied	  by	  the	  decrease	   in	  ventricular	  concentration	  of	   immunoreactive	  ANF,	   while	   atrial	   protein	   concentration	   was	   not	   changed	   compared	   to	   the	  control	  rats.	  In	  vitro	  studies	  with	  the	  isolated	  hearts	  showed	  that	  hypertensive	  ventricles	   contributed	   28%	   of	   the	   total	   ANF	   released,	   while	   normotensive	  ventricles	  contributed	  only	  8%.	  These	  experiments	  suggest	  that	  excess	  ANF	  is	  released	   from	   the	   ventricular	   stores43.	   However,	   in	   the	   settings	   of	   right	  ventricular	  hypertension,	  right	  atrial	  content	  as	  well	  as	  whole	  heart	  content	  of	  ANF	  was	  decreased44,	  indicating	  atrial	  secretion	  of	  ANF.	  The	  difference	  can	  be	  explained	   by	   the	   differences	   in	   complex	   regulation	   of	   NPs	   release	   from	   the	  secretory	   granules	   and	   their	   de	   novo	   synthesis	   from	   an	   increased	   pool	   of	  mRNA.	  Temporal	  regulation	  of	  ANF	  and	  BNP	  enhanced	  expression	  is	  also	  different	  in	  various	  conditions	  of	  cardiac	  disorders.	  After	  myocardial	  infarction,	  induced	  by	  isoproterenol	  injections	  in	  rats,	  BNF	  mRNA	  was	  upregulated	  in	  both	  ventricles	  at	   18	   h	   after	   injection,	   whereas	   ANF	   mRNA	   level	   gradually	   increased	   until	  significant	   levels	  3	  days	  after	   isoproterenol	  administration45.	  The	  same	   trend	  was	  observed	  in	  rats	  with	  aortocaval	  shunt,	  where	  both	  ANF	  and	  BNP	  plasma	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levels	  were	   steady	   elevated	   at	   1	   day	   and	  7	  days	   after	   surgery.	   Expression	  of	  BNF	  was	  induced	  only	  at	  1	  day	  after	  volume	  overload,	  but	  upregulation	  of	  ANF	  mRNA	  followed	  that	  of	  BNP	  only	  in	  7	  days	  after	  surgery46,47.	  Acute	  ventricular	  overload	   after	   MI48,49	   ,	   hypertension50	   and	   volume	   overload51	   leads	   to	   rapid	  and	  sometimes	  transient	  upregulation	  of	  BNP	  mRNA	  in	  the	  affected	  ventricular	  myocardium,	  whereas	  ANF	  upregulation	  follows	  BNP	  at	  later	  time	  points.	  The	  mechanisms	   of	   ANF	   and	   BNP	   gene	   expression	   are	   regulated	   by	   various	  stimuli	  like	  mechanical	  stress,	  growth	  factors	  and	  G	  protein-­‐coupled	  receptors.	  The	  expression	  of	  ANF	  and	  BNP	  in	  mechanical	  stress	  were	  studied	  in	  isolated	  cardiomyocytes,	   and	   atrial	   and	   ventricular	   preparation	   to	   separate	   the	  response	   of	   cardiomyocytes	   to	   strain	   from	   systemic	   response	   induced	   by	  neurohumoral	   factors.	   Mechanical	   stretch	   induces	   ANF,	   BNP	   and	   skeletal	  alpha-­‐actin	   mRNA	   expression	   in	   neonatal	   ventricular	   cardiomyocytes36	   and	  atrial	   preparations52,53,54.	   The	   signal	   from	  mechanically-­‐strained	   extracellular	  matrix	  propagates	  through	  the	  integrins	  and	  a	  cascade	  of	  intracellular	  kinases	  to	  activate	  p38	  MAP	  kinase	  and	  NF-­‐kB55,56	  and	  promote	  binding	  of	  the	  latter	  to	  shear	   stress-­‐responsive	   elements	   (SSREs)	   in	   the	   BNP	   promoter.	   In	   parallel	  with	  direct	  activation	  of	  BNP	  through	  p38	  MAPK,	  mechanical	  strain	  stimulated	  synthesis	  of	  AngII	  and	  ET-­‐1,	  which	  induced	  the	  ERK-­‐signaling	  pathway	  acting	  on	  the	  BNP	  promoter57,58.	  Several	  neurohumoral	  factors	  are	  involved	  in	  the	  hypertrophy	  response	  of	  the	  heart,	   including	  activation	  expression	  and	  secretion	  of	  ANF	  and	  BNP.	  AngII	   is	  the	   main	   effector	   of	   the	   renin–angiotensin	   system,	   and	   was	   found	   to	   be	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involved	   in	   hypertrophy	   remodeling	   through	   activation	   of	   AT1	   receptors	   on	  cardiomyocytes,	   fibroblasts	   and	   smooth	  muscle	   cells	  within	   the	   heart,	  which	  triggers	   G	   protein-­‐coupled	   and	   non-­‐G	   protein-­‐coupled	   signaling	   pathways	  including	  MAP	   kinases	   (ERK	   1/2,	   JNK,	   p38MAPK),	   receptor	   tyrosine	   kinases	  (PDGF,	  EGFR,	  insulin	  receptor),	  non-­‐receptor	  tyrosine	  kinases	  (Src,	  JAK/STAT,	  FAK)	  and	  reactive	  oxygen	  species.	  The	   production	   of	   TGFα	   stimulated	   by	   AngII	   in	   cardiac	   myocytes	   and	  fibroblasts59,	   thereby	   influencing	   the	   regulation	  of	  NPs	   through	  TGFα-­‐GATA4	  pathway60.	  	  Analysis	  of	  ANF	  expression	  and	  regulation	  during	  development	  of	  the	  heart	  has	  provided	  important	  mechanistic	  insights	  into	  the	  development	  of	  the	  chamber	  myocardium	  and	  the	  conduction	  system	  of	  the	  heart.	  	  In	  conclusion	  analysis	  of	  transcriptional	  regulation	  of	  ANF	  and	  BNP	  in	  different	  animal	  models	  of	  cardiomyopathy	  demonstrated	  the	  use	  of	  NPs	  in	  biomedical	  research	  to	  assess	  hypertrophic	  response	  in	  the	  development	  of	  HF,	  which	  is	  in	  agreement	  with	  their	  extensive	  application	  as	  biomarkers	  in	  a	  broad	  range	  of	  cardiovascular	  diseases	  in	  clinical	  practice.	  
	  
Small	  G-­‐proteins:	  activation	  and	  biological	  roles	  Rho	  GTPases	  of	  the	  Ras	  superfamily	  are	  involved	  in	  the	  regulation	  of	  multiple	  cell	   functions	  and	  have	  been	  implicated	  in	  the	  pathogenesis	  of	  cardiovascular	  diseases	  like	  heart	  hypertrophy	  and	  atherosclerosis.	  The	  Rho	  family	  comprises	  22	  genes	  encoding	  at	  least	  25	  proteins	  in	  humans,	  including	  the	  Rho,	  Rac,	  and	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Cdc42,	   proteins	   playing	   a	   fundamental	   role	   in	   cell	   biology.	   Two	   regulatory	  steps	   are	   required	   for	   the	   full	   activation	   of	   Rho	   proteins,	   the	   isoprenylation	  process	   for	   the	   translocation	   in	   membrane	   and	   the	   binding	   to	   the	   GTP61,62	  (Figure2).	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C	  is	  the	  cysteine	  that	  is	  geranylgeranylated.	  In	  membrane	  Rho	  family	  members	  bind	  GTP,	  and	  most	  exhibit	  GTPase	  activity	  and	  cycle	  between	  an	  inactive	  GDP-­‐bound	  form	  and	  an	  active	  GTP-­‐bound	  form.	  This	   cycling	   is	   finely	   regulated	   by	   three	   groups	   of	   proteins:	   the	   guanine	  nucleotide	   exchange	   factors	   (GEFs)	   as	   activators;	   the	   GTPase	   activating	  proteins	  (GAPs)	  and	  GDP	  dissociation	  inhibitors	  (GDIs)	  as	  negative	  regulators.	  When	   bound	   to	   GTP,	   Rho	  GTPases	   interact	  with	   their	   downstream	   effectors,	  which	   include	   protein	   kinases,	   regulators	   of	   actin	   polymerization,	   and	   other	  proteins	  with	  adaptor	  functions.	  The	  selective	  interaction	  of	  the	  different	  Rho	  GTPases	   with	   a	   variety	   of	   effectors	   determines	   the	   final	   outcome	   of	   their	  activation.	  The	  best	  characterized	  function	  of	  Rho	  family	  proteins	  is	  the	  regulation	  of	  the	  actin	  cytoskeleton,	  with	  RhoA	   involved	   in	   the	   formation	  of	  actin	  stress	   fibers	  and	   focal	  adhesion	  complexes,	  Rac1	   in	   facilitating	  actin	  polymerization	  at	   the	  cell	   periphery	   to	   generate	   protrusive	   actin-­‐rich	   lamellipodia	   and	   membrane	  ruffling,	  and	  Cdc42	  in	  the	  formation	  of	  filopodia63.	  From	  these	  evidences	  it	  has	  been	   hypothesized	   a	   direct	   involvement	   of	   the	   Rho	   proteins	   in	   the	  fibroproliferative	   and	  hypertrophic	   responses	   associated	  with	   cardiovascular	  diseases,	  such	  as	  atherosclerosis	  and	  cardiac	  hypertrophy.	  	  In	   a	   study	   of	   pathway-­‐based	   genome-­‐wide	   association	   analysis	   has	   recently	  identified	   Rac1	   as	   one	   of	   the	   biologically	   important	   gene	   in	   coronary	   heart	  diseases.	   The	   role	   of	   the	   small	   GTPase	   Rac1	   in	   cardiac	   hypertrophy	   and	  atherosclerosis	  has	  also	  been	  documented	  in	  clinical	  studies	  with	  the	  HMG-­‐CoA	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reductase	   inhibitors,	   and	   in	   in	  vitro	  and	   in	  vivo	  settings	  using	   transgenic	   and	  knock-­‐out	  mice.	   Thus,	   Rac1	   has	   emerged	   as	   a	   new	   possible	   pharmacological	  target	  for	  the	  treatment	  of	  cardiovascular	  diseases.	  	  
	  
Small	  G-­‐proteins	  and	  heart	  hypertrophy	  The	  low-­‐molecular-­‐weight	  or	  small	  GTPase	  superfamily	  consists	  of	  more	  than	  100	   members.	   They	   are	   divided	   into	   5	   subfamilies:	   (1)	   Ras,	   (2)	  Rho/Rac/cdc42,	  (3)	  Arf/Sar1,	  (4)	  Rab,	  and	  (5)	  Ran.	  All	  monomeric	  G	  proteins	  are	  characterized	  for	  their	  specificity	  for	  regulation	  of	  cell	  structure64.	  From	   this	   family,	   Ras,	   was	   the	   first	   small	   GTPase	   protein	   linked	   to	   cardiac	  remodeling,	   it	   is	   the	   most	   extensively	   characterized	   of	   the	   family	   in	   the	  myocardial	  setting65.	  In	  a	  second	  moment,	  the	  Rho/Rac/cdc42	  family	  has	  received	  greatest	  attention	  for	   their	   actions	   in	   myocardial	   cells	   and,	   of	   the	   20	   known	   Rho	   family	   gene	  products,	   the	   most	   extensively	   characterized	   members	   for	   the	   myocardial	  signaling	  was	  Rac1	  and	  RhoA.	  The	   effects	   of	  RhoA	  and	  Rac1	  on	   the	   actin	   cytoskeleton	   and	   cell	  morphology	  are	   mediated	   through	   stimulation	   of	   downstream	   effector	   kinases	   by	   the	  activated	   Rho-­‐GTP	   proteins66.	   For	   RhoA,	   the	   best	   known	   effectors	   are	   Rho	  kinase	   (ROCK)	   and	   mammalian	   diaphanous	   (mDia)67.	   ROCK	   phosphorylates	  the	  myosin	  binding	  subunit	  of	  myosin	  light	  chain	  (MLC)	  phosphatase	  resulting	  in	  increased	  myosin	  phosphorylation	  and	  contraction68.	  The	  discovery	  of	  a	  role	  for	   RhoA-­‐	   and	   ROCK-­‐	   mediated	   myosin	   phosphorylation	   in	   vascular	   smooth	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muscle	   contraction68,69,70,	   the	   finding	   that	   RhoA	   activity	   is	   upregulated	   in	  hypertension	  and	  the	  demonstrated	  efficacy	  of	  the	  ROCK	  inhibitor	  Y-­‐27632	  in	  lowering	   blood	   pressure	   have	   convincingly	   demonstrated	   involvement	   of	  RhoA/ROCK	   signaling	   in	   hypertension71,72,73.	   RhoA	   and	   ROCK	   signaling	  pathways	  have	  also	  been	  implicated	  in	  cerebrovascular	  stroke	  and	  in	  vascular	  endothelial	  permeability.	  The	  role	  of	  RhoA	   in	  vivo	  were	  studied	   from	  Several	   transgenic	  and	  knockout	  mouse	   models	   have	   been	   examined	   to	   delineate	   the	   role	   of	   RhoA	   signaling	  pathways	   in	   vivo.	   In	  work	   from	  Sah	   et	   al	  were	   generated	   transgenic	  mice	   in	  which	  constitutively	  activated	  (L63A)	  RhoA	  or	  wild-­‐type	  RhoA	  were	  expressed	  in	  a	  cardiac	  specific	  manner	  through	  the	  α-­‐MHC	  promoter74.	  Most	  founders	  and	  progeny	   of	   the	   activated	   RhoA	   lines	   did	   not	   survive	   to	   adulthood.	   Mice	  expressing	   wild-­‐type	   RhoA	   also	   showed	   increased	   mortality,	   which	   was	  dependent	   on	   gene	   dose	   and	   modestly	   rescued	   by	   backcrossing	   into	   a	   C57	  (versus	   Black	   Swiss)	   line	   to	   give	   50%	   survival	   at	   approximately	   3	   months.	  surprisingly,	   these	   mice	   did	   not	   develop	   an	   obvious	   hypertrophic	   response.	  Although	   both	   ANF	   and	   α-­‐MHC	   expression	   were	   increased,	   there	   was	   no	  significant	   increase	   in	   ventricular	   weight	   to	   tibial	   length,	   nor	   was	   there	   an	  increase	   in	   cardiomyocyte	   size.	   On	   the	   other	   hand,	   evidence	   of	   heart	   failure	  was	   seen	   in	   RhoA	   transgenics,	   with	   severe	   edema,	   ventricular	   chamber	  dilation,	   increased	   cardiac	   fibrosis,	   atrial	   enlargement,	   and	   decreased	  fractional	  shortening.	  It	  is	  not	  clear	  what	  underlies	  the	  failure	  of	  in	  vivo	  RhoA	  expression	   to	   mimic	   the	   in	   vitro	   hypertrophic	   phenotype,	   but	   effects	   on	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postnatal	   development,	   compensatory	   responses,	   or	   the	   more	   prolonged	  duration	   of	  RhoA	   expression	   are	   possibilities.	   It	   is	   also	   notable	   that	   a	   recent	  study	  using	  animals	  in	  which	  the	  RhoA	  effector,	  ROCK1,	  was	  partially	  deleted	  (ROCK1	   haploinsufficient	   mice)	   did	   not	   show	   decreased	   hypertrophy	   but	  rather	  decreased	  fibrosis75.	  Applying	  these	  data	  to	  the	  observations	  made	  with	  the	   cardiac	   RhoA	   transgenic	   mouse	   suggests	   the	   possibility	   that	   RhoA	   in	  cardiomyocytes	   could	   act	   through	   a	   ROCK-­‐dependent	   paracrine	   pathway	   to	  alter	  cardiac	  fibroblast	  proliferation.	  Another	  striking	  observation	  made	  in	  the	  RhoA	   transgenic	   mice	   was	   that	   many	   developed	   atrial	   fibrillation	   and	  atrioventricular	   (AV)	   block,	   as	   well	   as	   severe	   bradycardia,	   with	   heart	   rates	  nearly	   half	   those	   of	   nontransgenic	   littermate	   controls74.	   Effects	   on	   the	  conduction	   system	  could	   reflect	   effects	   of	  RhoA	   in	  modulating	   the	   activity	  of	  cardiac	  ion	  channels.	  However,	   is	   unclear	   whether	   the	   observed	   salutary	   effect	   of	   blocking	  RhoA/Rho	   kinase	   signaling	   reflects	   changes	   in	   the	   cardiomyocyte	   or	   is	   a	  consequence	   of	  more	  directly	   inhibiting	   fibroblast	   proliferation/migration	  or	  of	  attenuating	  local	  inflammatory	  responses.	  There	  is	  evidence	  that	  Rho	  can	  be	  activated	  in	  cardiac	  fibroblasts	  and	  affect	  their	  proliferation76.	  Indeed	  the	  study	  cited	  above	  using	  ROCK	  1	  haploinsufficient	  (-­‐/+)	  mice	  supports	  the	  notion	  that	  a	   critical	   function	   for	   RhoA/ROCK1	   could	   reside	   in	   the	   fibroblast	   where	   it	  mediates	  perivascular	  fibrosis	  induced	  by	  TAC,	  myocardial	  infarction,	  or	  Ang	  II.	  Determining	  whether	  acute	  activation	  of	  RhoA	  and	  ROCK	  signaling	  pathways	  within	   the	   myocyte	   serve	   protective	   or	   deleterious	   functions	   is	   critical	   to	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understanding	  the	  utility,	  timing,	  and	  targets	  of	  inhibition	  of	  RhoA	  signaling.	  For	   Rac1	   activation	   two	   predominant	   effector	   response	   pathways	   lie	  downstream	   in	   cellular	   signaling:	   induction	   of	   cytoskeletal	   remodeling	   and	  formation	   of	   ROS.	   A	   diverse	   team	   of	   cytoskeletal	   remodeling	   proteins	   are	  influenced	  by	  Rac1	  and	  referred	   to	  by	  acronyms	  or	  unintuitive	  abbreviations	  including	  WASP	  (Wiskott–Aldrich	  syndrome	  protein),	  WAVE	  (WASP	  with	  a	  V-­‐domain),	   IQGAP	   (calmodulin-­‐binding	   GTPase	   activating	   proteins),	   and	   PAK	  (p21-­‐activated	  kinase)77.	  PAK	  shows	  homology	  to	  another	  kinase	  that	  binds	  to	  Rac1	  named	  mixed	   lineage	  kinase	  3	  (MLK3)	  that,	  on	  activation,	  promotes	  the	  MEKK-­‐SEK-­‐JNK	   signaling	   cascade78.	   Our	   understanding	   of	   how	   cytoskeletal	  dynamics	   in	   the	  myocardium	   is	   regulated	   by	   this	   alphabet	   soup	   of	   factors	   is	  very	   rudimentary,	   but	   at	   least	   PAK	   has	   achieved	   visibility	   in	   regulation	   of	  contractility79.	   The	   cardiovascular	   literature	   is,	   in	   contrast,	   replete	   with	  examinations	  of	  ROS-­‐	  mediated	  effects	  that	  can	  be	  triggered,	  at	  least	  in	  part,	  by	  Rac1	  binding	  to	  p67	  phox,	  leading	  to	  activation	  of	  the	  NADPH	  oxidase	  system.	  The	   subsequent	   generation	   of	   ROS,	   which	   cascades	   into	   multiple	  cardiovascular	   effects	   including	   hypertrophy,	   hypertension,	   atherosclerosis,	  chemotaxis,	   and	  platelet	   aggregation,	   has	   been	   recently	   summarized80	   and	   is	  considered	  elsewhere	  in	  this	  thematic	  series.	  Studies	  using	  activated	  or	  dominant	  interfering	  mutants	  of	  RhoA	  or	  Rac1	  have	  implicated	   these	  proteins	   in	  numerous	  pathways	   regulating	   gene	   expression.	  Among	   the	   earliest	   described	   effects	   of	   RhoA	   was	   its	   ability	   to	   elicit	   serum	  response	   element	   (SRE)-­‐mediated	   transcriptional	   activation	   through	   a	   TCF-­‐
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independent,	  SRF-­‐mediated	  pathway.	  In	  addition,	  RhoA	  has	  been	  implicated	  in	  transcriptional	   activation	   of	   AP-­‐1,81,82	   GATA-­‐4,83	   nuclear	   factor	   (NF)-­‐κB,84,85	  and	   MEF2	   pathways86,87.	   For	   Rac1,	   activation	   of	   MAPK	   kinase	   cascades	  upstream	   of	   c-­‐Jun	   N-­‐terminal	   kinase	   (JNK),	   and	   p38	   elicits	   transcriptional	  changes.	   For	   example,	   regulation	   of	   target	   genes	   such	   as	   brain	   natriuretic	  peptide	  (BNP)	  or	  atrial	  natriuretic	  factor	  (ANF)	  are	  influenced	  by	  Rac1	  activity.	  Thus,	   there	   are	   numerous	   potential	   pathways	   by	   which	   RhoA	   or	   Rac1	  activation	   and	   signaling	   could	   contribute	   to	   the	  well-­‐described	   alterations	   in	  gene	  expression	  associated	  with	  cardiomyocyte	  hypertrophy	  and	  remodeling.	  	  
Role	  of	  small	  G	  protein	  Rac	  in	  the	  heart	  hypertrophy	  
In	  vitro	  evidence	  Experiments	   conducted	   by	   transfecting	   cardiomyocytes	   with	   a	   plasmid	  encoding	  for	  the	  constitutively	  active	  mutant	  of	  Rac1	  (V12Rac1)	  documented	  a	  profound	  effect	  on	  sarcomeric	  reorganization,	  increase	  cell	  size,	  and	  induction	  of	   ANF	   expression,	   although	   the	   dominant-­‐negative	  mutant	   of	   Rac	   (N17Rac)	  attenuates	   the	   morphological	   hypertrophy	   associated	   with	   phenylephrine	  stimulation88.	   Further	   investigations	   demonstrated	   that	   activation	   of	   Rac1	   in	  response	   to	   phenylephrine	   and	   endothelin-­‐1	   contributes	   to	   the	   hypertrophic	  adaptation	   of	   cultured	   cardiomyocytes	   by	   modulating	   the	   ERK	   cascades89.	  Differently,	  in	  the	  stretch-­‐induced	  hypertrophic	  response,	  Rac1	  increases	  p38–MAPK	  activity	  and	  protein	  synthesis90	  (Figure3).	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Figure3:	   Role	   of	   Rac/NADPH	   oxidase-­‐derived	   oxidative	   stress	   in	   the	  
development	   of	   cardiac	   hypertrophy.	   Rac1	   inhibition	   with	   dominant	  negative	   Rac	   mutant	   (Rac-­‐DN),	   Rac	   deletion	   (Rac−/−)	   or	   statin,	   inhibition	   of	  NADPH	   oxidase	   with	   deletion	   of	   gp47phox	   (gp47phox-­‐/-­‐)	   or	   gp91phox	  (gp91phox-­‐/-­‐),	  or	  antioxidant	  such	  as	  N-­‐acetyl-­‐L-­‐cysteine,	  could	  reverse	  these	  effects.	  Ang-­‐II,	  angiotensin	  II;	  GEF,	  guanine	  nucleotide	  exchange	  factor;	  PAK1,	  p21-­‐activated	  kinase	  1;	  TGFβ,	  transforming	  growth	  factor-­‐β;	  CTGF,	  connective	  tissue	  growth	  factor;	  EGFR,	  epidermal	  growth	  factor;	  MAPK,	  mitogen-­‐activated	  protein	   kinase;	   ASK1,	   apoptosis	   signal-­‐regulating	   kinase;	   NF-­‐κB,	   nuclear	  factor-­‐κB;	   ERK,	   extracellular	   signal-­‐regulated	   kinase;	   JNK,	   c-­‐Jun	   N-­‐terminal	  kinase.	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MAPK,	   and	   serum	   response	   factor;	   nevertheless,	   myocytes	   contractility	   is	  influenced	  by	  PAK91.	  Several	  profibrotic	  stimuli,	  including	  mechanical	  stretch,	  ischemia/reperfusion	  injury,	   phenylephrine,	   and	   angiotensin	   II,	   have	   been	   shown	   to	   promote	   the	  formation	   of	   ROS	   and	   Rac1	   activity.	   For	   instance,	   the	   overexpression	   of	  N17Rac1	   abrogates	   the	   mechanical	   stretch-­‐induced	   intracellular	   ROS	  generation	   in	   cardiomyocytes.	   The	   same	   dominant-­‐negative	   mutant	   of	   Rac1	  inhibits	   the	   angiotensinII	   stimulation	   of	   ROS	   production	   in	   isolated	  cardiomyocytes.	   Subsequent	   studies	   have	   then	   established	   a	   link	   between	  Rac1,	   ROS	   production,	   and	   nuclear	   factor-­‐kB	   (NF-­‐kB)	   activity	   in	   the	  cardiomyocytes	  hypertrophy.	  	  	  
In	  vivo	  evidence	  To	   explore	   the	   direct	   involvement	   of	   Rac1	   in	   cardiovascular	   disorders,	   both	  cardiac	   specific	   transgenic	   and	   knock-­‐out	   mice	   have	   been	   generated.	   Mice	  overexpressing	   the	   constitutively	   active	   form	   of	   Rac1	   clearly	   evidence	   a	  dramatic	   cardiomyopathy	  phenotype.	  While	  hearts	   from	  non-­‐transgenic	  mice	  show	   a	   progressive	   increase	   of	   size	   consistent	   with	   rapid	   postnatal	   growth,	  those	   from	   transgenic	  mice	  are	  enlarged	  with	   severely	  dilated	   chambers	  and	  thin	  ventricular	  walls.	  Atria	  are	  also	  increased	  in	  size	  although	  at	  lower	  extent.	  This	   phenotype	   was	   hypothesized	   to	   be	   the	   results	   of	   a	   deregulation	   of	  signaling	   by	   Rac1	   and	   PAK,	   followed	   by	   loss	   of	   systolic	   function,	   and	   lethal	  dilated	   cardiomyopathy.	   Indeed,	   the	   absence	   of	   overt	   myofibril	   disruption	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cardiomyocytes	  of	  transgenic	  mice	  suggests	  that	  heart	  failure	  is	  not	  caused	  by	  loss	  of	  myofibril	  organization.	  Differently	   from	  the	  dilated	  hearts	  observed	   in	  young	   mice	   expressing	   the	   constitutively	   active	   form	   of	   Rac1	   that	   died	  spontaneously	  within	  3	  weeks	  after	  birth,	  hypertrophy	  becomes	  the	  dominant	  phenotype	   in	   juvenile	  mice	  associated	  with	  an	   increase	  of	  heart/body	  weight	  ratio,	  thickening	  of	  ventricular	  walls	  and	  loss	  of	  ventricular	  chamber	  area.	  A	   subsequent	   study	   was	   performed	   by	   generating	   the	   cardiac	   specific	   Rac1	  knockout	  mice;	  these	  mice	  were	  subjected	  to	  a	  hypertensive	  stress	  by	  infusing	  angiotensin	   II.	   Despite	   similar	   increases	   in	   systolic	   blood	   pressure,	  mice	   not	  expressing	  Rac1	   in	  the	  myocardium,	  do	  not	  develop	  cardiac	  hypertrophy	  and	  show	  a	  significant	  reduction	  in	  end-­‐diastolic	  myocardial	  wall	  thickness	  and	  left	  ventricular	   mass.	   These	   effects	   were	   associated	   to	   a	   smaller	   induction	   of	  cardiac	   fetal	   gene	   expression	   such	   as	  ANF,	  BNP,	  α-­‐skeletal	   actin,	   and	  myosin	  light	  chain	  2	  ventricular	  isoform.	  The	  protective	  effect	  of	  the	  absence	  of	  Rac1	  in	  the	   heart	   was	   associated	   with	   the	   inhibition	   of	   NADPH	   oxidase-­‐dependent	  generation	   of	   O2-­‐·	   and	   NF-­‐κB	   transcriptional	   activity.	   Consistent	   with	   these	  findings	  ZmRacD	  transgenic	  mice,	   that	  express	  a	  constitutively	  active	   form	  of	  Rac1,	   spontaneously	   develop	   a	   distinct	   cardiac	   phenotype	   manifested	   by	  cardiac	   hypertrophy,	   relative	   ventricular	   chamber	   dilation,	   and	   moderate	  systolic	  dysfunction92.	  These	  mice	  are	  also	  more	  susceptible	   to	  post-­‐ischemic	  injury	  and	  develop	  significantly	  larger	  myocardial	  infarcted	  area.	  Interestingly,	   the	   gene	   deletion	   of	   the	   small	   GTPase	   protein	   Cdc42,	   which	  belongs	   to	   the	   same	   family	  of	  Rac1	  and	   shares	   similar	  GEFs,	  makes	   the	  mice	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more	  susceptible	  to	  develop	  cardiac	  hypertrophy,	  following	  pressure	  overload.	  This	   function	   for	   Cdc42	   is	   unique	   among	   the	   Rho	   GTPase,	   as	   Rac1,	   Ras,	   and	  RhoA	   have	   all	   been	   shown	   to	   facilitate	   cardiac	   hypertrophy	   or	  myopathy	   in	  genetically	  modified	  mice,	   and	   indicates	   the	   importance	   to	   develop	   selective	  Rac1	  inhibitors	  in	  order	  to	  have	  a	  potential	  cardioprotective	  effect.	  Taken	   together	   the	   effect	   of	   Rac1	   on	   cardiac	   hypertrophy	   has	   been	  demonstrated	   by	   both	   in	   vitro	   and	   in	   vivo	   experimental	   conditions	   either	   by	  regulating	   actin	   cytoskeletal	   assembly	   and	   sarcomeric	   organization	   or	   the	  oxidative	  stress	  by	  assembling	  the	  NADPH	  oxidase.	  	  
Clinical	  evidences	  In	  patients	  with	  chronic	  heart	   failure,	   increased	  oxidative	  stress	   is	  associated	  with	  reduced	  left	  ventricular	  (LV)	  function	  and	  correlates	  with	  the	  severity	  of	  the	  disease93,94.	  Many	  animal	  studies	  suggests	  that	  in	  cardiomyocytes,	  NADPH	  oxidase	   may	   be	   a	   relevant	   source	   of	   ROS	   in	   cardiac	   hypertrophy	   and	  failure95,96.	  Rac1	  must	  be	  prenilated	  for	  its	  translocation	  in	  membrane	  and	  its	  subsequent	  activation	  with	  exchange	  of	  GDP	  for	  GTP	  at	  its	  regulatory	  domain	  its	  a	  critical	  process	   in	  the	  activation	  of	  NADPH	  oxidase,	  moreover	  the	  activation	  of	  Rac1-­‐GTPase	   mediates	   cellular	   hypertrophy	   of	   cardiac	   myocytes	   in	   experimental	  systems97,98.	  The	  prenilation	   step	   is	   inhibited	  by	   statins	   reducing	   translocation	  of	  Rac1	   to	  the	   cell	   membrane,	   therefore	   the	   inhibition	   of	   Rac1	   by	   statins	   decreases	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NADPH	  oxidase–related	  ROS	  production	   in	  vascular	   smooth	  muscle	   cells	   and	  cardiac	  myocytes	  and	  reduces	  cardiac	  hypertrophy	  in	  both	  in	  vitro	  and	  animal	  experiments99–101	   these	   therapeuthic	   effects	   are	   correlated	   to	   the	   so	   called	  pleyotropic	  effects	  of	  statins.	  In	  patients	  affected	  by	  chronic	  heart	  failure	  which	  is	  associated	  a	  reduced	  left	  ventricular	  function	  was	  observed	  an	  increased	  oxidative	  stress	  and	  correlates	  with	  severity	  of	  the	  disease.	  Although	  the	  source	  of	  ROS	  in	  chronic	  heart	  failure	  remains	   to	   be	   elucidated,	   emerging	   evidences	   suggest	   that	   Rac1-­‐mediated	  NADPH	   oxidase	   activation	   plays	   a	   prominent	   role.	   The	   administration	   of	  statins,	   has	   also	   shown	   to	   significantly	   inhibits	   myocardial	   Rac1-­‐GTPase	  activity	   with	   a	   potential	   beneficial	   effects	   for	   patients	   with	   chronic	   heart	  failure102.	  Statins	  also	  improves	  redox	  state	  in	  saphenous	  vein	  grafts	  in	  patients	  undergoing	   to	   coronary	   artery	   bypass	   grafting	   by	   inhibiting	   Rac1-­‐mediated	  activation	   of	   NADPH	   oxidase,	   further	   confirming	   the	   central	   role	   of	   Rac1	   in	  cardiac	  heart	  failure	  and	  hypertrophy.	  In	   human	   failing	  myocardium,	   upregulation	   of	   Rac1	   and	   p47phox	  membrane	  protein	  expression	  as	  well	  as	  increased	  Rac1-­‐GTPase	  activity	  may	  resemble	  the	  underlying	  mechanisms	  for	  increased	  oxidase	  activity.	  However,	   especially	   in	   human	   myocardium,	   the	   precise	   mechanisms	   of	   this	  link	  require	  additional	  investigations.	  Because	  activation	  of	  Rac1-­‐GTPase	  may	  contribute	   to	   the	   development	   of	   heart	   failure,	   so	   from	   the	   threatment	  with	  statin	  is	  attempted	  to	  inhibit	  Rac1	  in	  human	  myocardium.	  To	   address	   these	   issues,	   patients	   awaiting	   elective	   coronary	   bypass	   surgery	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were	   prospectively	   treated	   with	   pravastatin,	   atorvastatin,	   or	   without	   statin.	  After	  4	  weeks	  of	  statin	  treatment,	  activity	  as	  well	  as	  expression	  of	  Rac1	  in	  right	  atrial	   myocardium	   was	   significantly	   reduced	   compared	   with	   untreated	  controls.	  Therefore	   the	   increased	   Rac1-­‐GTPase	   activity	   is	   associated	   with	   enhanced	  NADPH	   oxidase–related	   ROS	   production.	   Furthermore,	   oral	   treatment	   with	  both	   a	   lipophilic	   and	   a	   hydrophilic	   statin	   inhibits	   Rac1-­‐GTPase	   activity	   and	  reduces	   Ang	   II–induced	   NADPH	   oxidase	   activity	   in	   atrial	   myocardium.	  However	   a	   prospective,	   randomized	   clinical	   trial	   is	   necessary	   to	   address	  whether	  statin	  treatment	  is	  beneficial	  in	  patients	  with	  chronic	  heart	  failure.	  Further	   confirm	   that	   Rac	   is	   strongly	   related	   to	   cardiovascular	   disease	   in	  human,	   in	   patients	  with	   end-­‐stage	  heart	   failure	  with	  dilated	   cardiomyopathy	  and	   ischemic	   cardiomiopathy	   were	   observed	   that	   Rac1-­‐GTPase	   activity	   was	  upregulated	  3-­‐fold	  compared	  with	  non	  failured	  myocardium102.	  	  
The	  pathogenesis	  of	  atherosclerosis	  	  Atherosclerosis	   is	   a	   multifactorial	   disease	   that	   involves	   the	   vascular	   district	  causing	   the	   occlusions	   of	   large	   conduit	   arteries	   such	   as	   aorta	   and	   iliac	   and	  medium	  caliber	  as	  coronary,	  carotid	  and	  femoral	  arteries.	  This	  disease	  is	  responsible	  for	  the	  onset	  of	  pathological	  vascular	  events	  such	  as	  myocardial	   infarction	   and	   stroke	  which	   are	   the	  main	   cause	   of	  mortality	   and	  morbidity	  in	  the	  United	  States,	  Europe	  and	  Japan103.	  	  Arteries	  are	  constituited	  by	  three	  different	  layers:	  the	  tunica	  intima,	  media	  and	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adventitia	   .The	   tunica	   intima	   is	   the	   innermost	   layer	   of	   the	   vessel	  wall	   and	   is	  constituted	   by	   a	   thin	   internal	   layer	   of	   endothelial	   cells	   that	   separates	   the	  lumen	  to	  artery	  wall.	  The	  cells	  belonging	  to	  this	  layer	  express	  proteins	  such	  as	  nitric	   oxide	   synthase	   and	   thrombomodulin	   that	   in	   normal	   conditions	   confer	  anti-­‐adhesive	   and	   antithrombotic	   properties	   to	   the	   vessel	   wall.	   The	   tunica	  media	   is	  composed	  of	  smooth	  muscle	  cells	  and	   from	  the	  extracellular	  matrix.	  Tunica	  intima,	  unlike	  the	  tunica	  media,	  generally	  does	  not	  vary	  with	  aging.	  The	  tunica	   adventitia	   is	   separated	   from	   the	  media	   by	   the	   external	   elastic	   lamina	  and	  is	  composed	  mainly	  of	  fibroblasts,	  collagen	  and	  glycosaminoglycans	  .	  The	   endothelial	   dysfunction	   leads	   to	   an	   injury	   and	  a	   compensatory	   response	  that	  alters	  the	  normal	  homeostatic	  properties	  of	  the	  endothelium	  and	  involve	  an	   increase	   in	   the	   adhesiveness	   of	   leukocytes	   and	   platelets.	   Cellular	   damage	  also	   induces	   the	   endothelium	   to	   have	   procoagulant	   properties	   and	   form	  vasoactive	   molecules,	   cytokines	   and	   growth	   factors.	   These	   factors	   make	   the	  injury	  a	  favorable	  environment	  for	  the	  formation	  of	  thrombosis.	  The	  inflammatory	  response	  also	  stimulates	  the	  migration	  and	  proliferation	  of	  SMC	   that	   migrate	   from	   the	   tunica	   media	   to	   the	   intima.	   If	   these	   responses	  continue	  undisturbed	  can	  thicken	  the	  artery	  wall	  which	  will	  compensate	  with	  a	  gradual	   expansion	   to	   keep	   the	   diameter	   of	   the	   lumen	   unaltered,	   this	  phenomenon	   is	   called	   	   "Glagov"	   or	   remodeling104.	   The	   continuous	  inflammatory	   state,	   moreover,	   involves	   an	   increase	   in	   the	   number	   of	  macrophages	   and	   lymphocytes	   that	   arrive	   from	   the	   bloodstream	   into	   the	  inflamed	   area	   and	   multiply	   within	   the	   lesion.	   This	   cycle	   of	   accumulation	   of	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mononuclear	  cells,	  migration	  and	  proliferation	  of	  smooth	  muscle	  cells	  and	  the	  formation	   of	   fibrous	   tissue	   involves	   the	   successive	   enlargement	   and	  remodeling	  of	   the	   lesion.	  These	  events	   lead	   to	   the	   formation	  of	  a	   fibrous	  cap	  that	  covers	  the	  lipid	  core	  and	  necrotic	  tissue103.	  Plaque	  rupture	  is	  a	  very	  dangerous	  event	  that	  can	  lead	  to	  myocardial	  infarction	  and	   cerebral	   stroke.	   To	   determine	   the	   rupture	   of	   the	   plaque	   there	   are	  many	  internal	   factors	   related	   to	   the	   structural	   characteristics	  of	   the	   lesion	  but	  also	  external	   factors.	   Histological	   studies	   of	   human	   atherosclerotic	   lesions	   have	  allowed	  to	  observe	  that	  the	  accumulation	  of	  macrophages	  and	  the	  presence	  of	  fibrous	  caps	  purposes,	  containing	  few	  smooth	  muscle	  cells,	  are	  characteristics	  of	  plaques	  "unstable"	  or	  more	  susceptible	   to	  rupture.	  The	  size	  and	   texture	  of	  the	   atheromatous	   core	   vary	   considerably,	   but	   both	   characteristic	   are	  important	  in	  order	  to	  evaluate	  the	  stability	  of	  the	  plaque:	  plaques	  containing	  a	  soft	   core	   are	   more	   subject	   to	   rupture	   and	   to	   originate	   acute	   ischemic	  pathologies.	  The	   lipids,	   as	   cholesterol	   esters,	   tend	   to	   soften	   the	   plaque,	  while	   cholesterol	  crystals	  have	  an	  opposite	  effect105,106.	  This	  theory	  is	  supported	  by	  observations	  made	  as	  a	  result	  of	   lipid-­‐lowering	   therapies	   in	  humans	   that	   lead	   to	  a	  general	  reduction	   of	   the	   content	   of	   cholesterol	   esters	   and	   to	   a	   relative	   increase	   of	  deposit	   of	   cholesterol	   crystals	   within	   the	   atheromatous	   core,	   factors	   that	  determine	  a	  greater	  plaque	  stability107.	  In	   the	   core	   of	   the	   plaque	   there	   is	   highly	   thrombogenic	  material	   and,	   for	   this	  reason,	  the	  fibrous	  caps	  became	  fundamental	  to	  separate	  the	  core	  from	  vessel	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lumen	  avoiding	   that	   these	   two	  environments	  are	   in	  contact.	  The	   fibrous	  caps	  can	   vary	   greatly	   in	   thickness,	   number	   of	   cells,	   resistance,	   quantity	   and	  constitution	   of	   the	   matrix,	   however,	   a	   concept	   common	   to	   all	   is	   that	   the	  thinning	  of	   the	  cap	  and	  the	  reduction	  of	  collagen	  content	  and	  smooth	  muscle	  cells	  lead	  to	  increased	  susceptibility	  to	  break108.	  Among	   the	   various	   components,	   collagen	   plays	   a	   key	   role	   in	   order	   to	   confer	  resistance	  to	  the	  tissues	  and	  thus	  also	  to	  the	  fibrous	  cap,	  in	  fact,	  experimental	  evidences	  suggest	  that	  plaques	  containing	  lower	  concentrations	  of	  collagen	  are	  more	  prone	  to	  rupture	  compared	  to	  those	  rich	  in	  this	  protein109.	  	  
Role	  of	  Rac1	  in	  atherosclerosis	  Role	   in	   vascular	   smooth	   muscle	   cell	   proliferation,	   migration,	   and	  differentiation	  In	   advanced	   atherosclerotic	   lesions	   smooth	  muscle	   cells	   accumulation	   in	   the	  intima	  results	  from	  cell	  proliferation	  and	  directed	  migration	  of	  smooth	  muscle	  cells	   from	   the	  media110,111.	   These	   processes	   are	   regulated	   by	   various	   factors	  that	   are	   produced	   locally	   at	   the	   sites	   of	   vascular	   lesion	   by	   macrophages,	   T-­‐lymphocytes,	   platelets,	   endothelial	   cells	   and	   smooth	   muscle	   cells	   (Figure4).	  Among	  these,	  platelet	  derived	  growth	  factor	  (PDGF)	  and	  tumor	  necrosis	  factor-­‐α	  (TNF-­‐α)	  are	  the	  best	  characterized112.	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Figure4.	  Role	  of	  Rac1	  in	  atherosclerosis.	  







	   34	  
interaction	  of	  Erk	  -­‐PAK	  -­‐β-­‐PIX	  protein	  complex	  with	  Rac.	  The	  Ahnak	  protein	  is	  indeed	   required	   for	   PDGF-­‐	   demonstrated	   that,	   in	   response	   to	   a	   chemotactic	  agent,	   localized	   Rac1	   activity	   and	   actin	   cytoskeleton	   assembly	   at	   the	   leading	  edge	  coordinate	  the	  smooth	  muscle	  cell	  migration.	  Smooth	  muscle	   cell	  migration	   in	   response	   to	   PDGF	   is	   also	   dependent	   by	   the	  activity	   of	   the	   NADPH	   oxidase	   which	   generates	   the	   ROS	   and	   the	  phosphorylation	  on	  Thr423	  of	   the	  Rac1	  effector	  PAK1116.	   In	  vitro	  stimulation	  of	   smooth	   muscle	   cells	   with	   thrombin	   upregulates	   the	   expression	   levels	   of	  Nox1,	   an	   inducible	   isoform	   of	   NADPH	   oxidase117,	   which	   modulates	   [Ca2+]i	  levels	  partially	  via	  influx	  of	  extracellular	  Ca2+.	  Small	  interfering	  RNA	  directed	  against	   Nox1	   blocks	   the	   basic	   fibroblast	   growth	   factor	   (bFGF)-­‐induced	   ROS	  generation	  as	  well	  as	  cell	  migration118.	  TNF-­‐α	  is	  another	  potent	  proinflammatory	  cytokine,	  produced	  by	  macrophages	  and	   and	   lymphocytes	   in	   atherosclerotic	   lesions	   and	   in	   the	   intima	   of	   arteries	  after	   injury	   that	   promotes	   the	   accumulation	   of	   smooth	  muscle	   cells119–121.	   In	  vitro	  experiments,	   conducted	   in	  human	  coronary	  artery	   smooth	  muscle	   cells,	  demonstrated	   that	   p38-­‐MAPK/CREB/Rac1	   pathway	   plays	   a	   critical	   role	   in	  TNF-­‐α-­‐	  induced	  smooth	  muscle	  cell	  migration122.	  The	  activity	  of	  Rac1	  influences	  also	  the	  transition	  of	  smooth	  muscle	  cells	  from	  the	  quiescent	  state	  to	  a	  synthetically	  active	  and	  proliferative	  phenotype	  in	  the	  vessel	   wall	   media.	   The	   expression	   of	   Rac1	   is	   enhanced	   under	   vessel	   cyclic	  strain	   and	   positively	   regulates	   h1-­‐calponin,	   a	   marker	   of	   contractile	  phenotype123.	  With	   this	   regard,	   type	   I	   fibrillar	   collagen,	   surrounding	   smooth	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muscle	  cells	   in	  the	  media,	  regulates	  cell	  behavior	  and	  Rac1-­‐dependent	  matrix	  metalloproteinase	  1	  expression124.	  Rac1	   is	   then	   required	   for	   smooth	  muscle	   cell	   proliferation	  by	   inducing	  Skp2,	  the	  F-­‐box	  component	  of	  the	  SCFSkp2	  ubiquitin-­‐ligase	  that	  promotes	  ubiquitin-­‐mediated	   proteosomal	   degradation	   of	   p27Kip1	   125,	   and	   by	   upregulating	   the	  cyclin	  D1	  mRNA	  70	  (Table	  2).	  Taken	  together,	  Rac1	  is	  a	  key	  signaling	  molecule	  activated	  by	  different	   cardiovascular	  agonists	  and	   involved	   in	  SMC	  migration	  proliferation	   and	   differentiation	   processes	   potentially	   associated	   with	  atherosclerotic	  plaque	  development.	  	  
Regulation	  of	  endothelial	  permeability	  and	  leukocyte	  diapedesis	  in	  the	  
vascular	  wall	  The	  movement	  of	   leukocytes	  from	  the	  blood	  into	  the	  arterial	  wall	  plays	  a	  key	  role	   in	   the	   inflammatory	   response	   associated	   to	   atherosclerosis126	   and	   the	  activation	   of	   integrin	   receptors	   on	   leukocytes,	   in	   response	   to	   adhesive	   and	  chemoattractant	   agonists,	   mediates	   their	   arrest	   on	   the	   endothelium	  monolayer.	   Spatially	   and	   temporally	   restricted	  Rac1	  activation	   to	   the	   leading	  edge	  is	  required	  during	  α4β1-­‐integrin	  dependent	  leukocyte	  migration	  on	  both	  the	   vascular	   ligand	   VCAM1	   (vascular	   cell	   adhesion	   molecule	   1)	   and	   on	   the	  extracellular	   matrix	   10	   protein	   fibronectin127.	   Furthermore	   the	   ligation	   of	  α4β1-­‐integrin	   directly	   regulates	   Rac1	   activation	   and	   leukocyte	   migration128.	  This	  event	   is	  considered	   to	  be	   just	  one	  of	   those	   that	  contributes	   to	   leukocyte	  transendothelial	  migration.	  Certainly	  other	  cues	   that	  drive	  migration,	  such	  as	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chemoattractants	  and	  signals	  generated	  by	  mechanical	  force	  on	  the	  cell	  (such	  as	   shear	   flow),	   will	   come	   into	   play	   to	   regulate	   Rac1	   activation	   and	   cell	  migration.	   The	   combined	   input	   of	   these	   cues	   will	   ultimately	   determine	   how	  and	   where	   leukocytes	   migrate.	   Moreover,	   the	   fact	   that	   both	   active	   and	  dominant	   negative	   form	   of	   Rac1	   inhibit	   macrophage	   migration	   suggests	   the	  requirement	   for	   a	   balanced	   and	   coordinated	   regulation	   of	   Rac1	   for	   a	   proper	  leukocyte	   migration129,130.	   Rac1-­‐dependent	   NF-­‐kB	   activation	   is	   also	   required	  for	   the	   subsequent	   flow-­‐induced	   surface	   expression	   of	   ICAM-­‐1131,	   which	   is	  involved	   in	   the	   recruitment	   of	   leukocytes	   into	   the	   atherosclerotic	   plaque.	  These	  evidences	  put	  Rac1	   in	  a	   central	   role	   into	   the	   leukocyte	  diapedesis	  and	  inflammation	  in	  response	  to	  vascular	  injury.	  Rac1	  becomes	  activated	  within	  5	  to	  30	  minutes	  after	  shear	  stress	  stimulation	  and	   is	   required	   for	   respreading	   and	   alignment	   of	   endothelial	   cells	   in	   the	  direction	   of	   flow	   132.	   The	   Rac1	   effector	   PAK	   is	   directly	   involved	   in	   the	  regulation	   of	   endothelial	   permeability	   and	   its	   inhibition,	   in	   vivo,	   reduces	  vascular	  permeability	  in	  atherosclerosis-­‐prone	  regions133,134.	  The	  effect	  of	  PAK	  on	  endothelial	  permeability	   is	  also	  associated	  with	   increase	  NF-­‐κB	  activation	  and	  probably	  involves	  both	  ROS	  and	  actin	  cytoskeleton	  reorganization134,135.	  In	  contrast	  with	  this	  observation,	  activated	  Rac1	  also	  promotes	  the	  breakdown	  of	  cell-­‐cell	   junctions	   and	   endothelial	   permeability136.	   The	   dual	   role	   of	   Rac1	   is	  probably	  dependent	  by	  the	  effector	  pathways	  that	  is	  recruited	  under	  different	  stimuli.	  Elevated	   permeability	   of	   the	   endothelium	   is	   believed	   to	   allow	   entry	   of	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lipoproteins	   into	   the	   vessel	   wall,	   which	   become	   oxidized	   and	   propagate	  endothelial	   dysfunction	   and	   foam	   cell	   formation.	   The	   endothelial	   barrier	  property	  is	  tightly	  regulated	  whereby	  IQGAP	  activation	  has	  been	  suggested	  to	  stabilize	   the	   adherens	   junctions136,	   whereas	   PAK	   activation	   is	   linked	   to	  increased	   endothelial	   cell	   permeability137.	   Thus,	   conditions	   that	   favor	  interaction	   of	   Rac1	   with	   PAK	   would	   lead	   to	   junctional	   disruption,	   whereas	  those	   that	   favor	   IQGAP	  would	   lead	   to	   junctional	   stabilization.	   The	   protective	  role	   of	   Rac1	   on	   the	   endothelial	   function	   has	   also	   been	   associated	   with	   the	  regulation	   of	   eNOS	   activity	   in	   vascular	   permeability	   is	   still	   debated	   and	  will	  need	  to	  be	  investigated	  in	  in	  vivo	  experimental	  models.	  	  
In	  vivo	  evidence	  on	  atherosclerosis	  The	  majority	  of	   currently	   reported	  data	  on	   the	   role	  of	  Rac1	   in	   atherogenesis	  are	   related	   to	   its	   functional	   role	   in	   the	  NADPH	  oxidase	  activity	  and	  oxidative	  stress.	  Different	  knock-­‐out	  mice	  have	  been	  generated	  with	  the	  aim	  to	  alter	  the	  oxidative	  balance	  or	  the	  function	  of	  redox-­‐	  sensitive	  proteins	  and	  transcription	  factors138,139,140,141,142,109-­‐113.	  Smooth	  muscle	  cells	  isolated	  from	  mice	  lacking	  the	  p47phox	  subunit	  of	   the	  NADPH	  oxidase	  show	  a	   lower	  superoxide	  production	  and	  a	   reduced	  proliferative	   index	   in	   response	   to	  growth	   factors	  compared	   to	  wild	  type	  mice141.	  ApoE-­‐/-­‐	  mice	  crossed	  with	  p47phox-­‐/-­‐	  mice	  develop	  smaller	  atherosclerotic	   lesions	   compared	   to	   apoE-­‐/-­‐	   single	   knock	   out,	   regardless	   the	  type	  of	  diet	  utilized141.	   In	   response	   to	  wire	   injury,	  gp91phox-­‐/-­‐	  mice	  develop	  smaller	   lesions	   in	   the	   femoral	   artery	   associated	   with	   less	   pronounced	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hyperproliferative	  response	  compared	  to	  wild	  type	  mice142.	  This	  effect	  seems	  to	   be	   the	   results	   of	   a	   lower	   proliferative	   capacity	   of	   smooth	   muscle	   cells	  gp91phox-­‐/-­‐142.	   A	   similar	   defect	   in	   cell	   proliferation,	   determining	   a	   lower	  neointima	   formation	   in	   response	   to	   vascular	   injury	   associated	   to	   lower	  activation	   state	   of	   Rac1,	   was	   observed	   in	   smooth	  muscle	   cells	   isolated	   from	  CHF1/Hey2-­‐/-­‐	   mice143.	   The	   CHF1/Hey2	   is	   a	   cardiovascular-­‐restricted,	   hairy-­‐related	   bHLH	   transcription	   factor,	   whose	   endothelial	   Rac1	   haploinsufficient	  mice144.Thus,	   the	   final	   outcome	   of	   Rac1	   inhibition	   or	   deletion	   leads	   to	  cardiomyopathy	   in	   adult	  mice145.	   The	   absence	   of	   CHF1/Hey2	   does	   not	   affect	  the	   expression	   of	   PDGF	   or	   EGF	   receptors,	   activation	   of	   the	   MAP	   kinases	  ERK1/2,	   p38,	   or	   activation	   of	   the	   survival	   kinase	   AKT	   but	   decreases	   Rac1	  activity	  and	  the	  Rac-­‐GEF,	  Sos1,	  expression138.	  The	  Rac1-­‐dependent	  generation	  of	  the	  ROS	  also	  mediates	  the	  effect	  of	  Ref-­‐1	  on	  PDGF-­‐induced	   smooth	   muscle	   cell	   migration140.	   Ref-­‐1	   is	   an	  apurinic/apyrimidinic	   endonuclease/redox	   factor-­‐1	   involved	   in	   the	   base	  excision	   repair	   pathways	   of	   DNA	   subjected	   to	   oxidative	   damage	   and,	   in	  addition,	  promotes	  a	  variety	  of	  redox	  mediated	  events.	  In	  smooth	  muscle	  cells,	  Ref-­‐1	  appears	  to	  be	  downstream	  of	  Rac1	  in	  the	  chemotactic	  response	  to	  PDGF,	  and	   its	   deletion	   determines	   a	   lower	   neointima	   formation	   in	   response	   to	  balloon	   injury140.	   Another	   factor	   linked	   to	   the	   oxidative	   response	   is	   the	  transcription	   factor	   nuclear	   factor	   erythroid	   2-­‐related	   factor	   2	   (Nrf2).	   Many	  studies	  have	  reported	  a	  pathophysiological	  role	  of	  Nrf2	  in	  protecting	  cells	  from	  oxidative	  stress	  and	  Nrf2	  null	  mice	  show	  enhanced	  neointima	  hyperplasia	  and	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higher	   basal	   and	   PDGF-­‐	   stimulated	   Rac1	   activity	   in	   smooth	   muscle	   cells139.	  Finally,	  the	  haploinsufficient	  mice	  for	  kalirin-­‐9,	  a	  protein	  abundantly	  expressed	  in	   smooth	   muscle	   cells	   containing	   two	   GEF	   domains	   for	   Rac1	   and	   RhoA,	  develop	  60%	  less	  neointima	  than	  WT	  mice.	  This	  effect	  was	  demonstrated	  to	  be	  associated	  to	  lower	  Rac1	  activation	  and	  to	  be	  smooth	  muscle	  cell	  specific146	  	  
Selective	  Rac	  inhibitors	  and	  their	  mechanism	  of	  action	  	  Before	   the	   development	   of	   new	   selective	   inhibitors,	   the	   pharmacological	  blockade	  of	  the	  small	  GTPases	  has	  been	  described	  with	  the	  use	  of	  the	  HMG-­‐CoA	  reductase	   inhibitors,	   statins147,	   and	   the	   prenyl	   transferase	   inhibitors	   148,149.	  Both	   type	   of	   agents	   inhibit	   the	   isoprenylation	   processes	   of	   different	  intracellular	   proteins	   and,	   thus,	   their	   activity	   in	   a	   nonselective	  manner.	   This	  nonlipid-­‐related	  effects	  of	  statins	  are	  thought	  to	  contribute	  to	  their	  protective	  action	  on	  cardiovascular	  events,	  thus	  supporting	  the	  development	  of	  selective	  inhibitors	  of	  the	  small	  GTPase	  proteins102,150,151.	  In	  in	  vitro	  and	  ex	  vivo	  analyses,	  indeed,	  have	  demonstrated	  that	  statins	  inhibit	  the	  isoprenylation	  and	  function	  of	   both	   RhoA	   and	   Rac1124,152.	   Moreover,	   a	   novel	   pleiotropic	   mechanism	   of	  statins	   has	   also	   been	   described	   that	   does	   not	   involve	   the	   isoprenylation	  process	  but	  the	  increase	  nuclear	  translocation	  and	  degradation	  of	  Rac1.	  These	  evidences	   supported	   the	   interest	   in	   the	   development	   of	   new	   selective	   Rac1	  inhibitors	  and	  to	  investigate	  their	  effect	  in	  cardiovascular	  diseases	  (Table1).	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Table1:	  Chemical	  structrure	  and	  molecular	  mechanisms	  of	  Rac	  inhibitors.	  	  
Rac1–GEF	  interaction	  inhibitors	  The	  determination	  of	  the	  crystal	  structure	  of	  the	  DH	  and	  PH	  domains	  of	  the	  T-­‐lymphoma	  invasion	  and	  metastasis	  factor	  1	  (Tiam1)	  GEF	  in	  complex	  with	  Rac1	  has	  provided	  detailed	   information	  on	  the	  mechanism	  and	  the	  specific	  sites	  of	  GEF-­‐Rac1	   interaction153.	   In	   particular,	   Trp56	   of	   Rac1	   is	   a	   critical	   site	   for	   the	  discrimination	  of	  a	  subset	  of	  GEF,	   including	  Tiam1	  and	  Trio154.	  These	  studies	  have	  allowed	  the	  identification	  of	  a	  polypeptide	  derived	  from	  the	  b3	  region	  of	  Rac1	   including	   Trp56	   that	   serves	   as	   a	   specific	   inhibitor	   for	   Rac1	   interaction	  with	   the	  GEFs.	  Further	   implementation	  of	   this	   study	   led	   to	   the	   identification,	  by	  a	  structure-­‐based	  virtual	  screening	  approach,	  of	  the	  first	  selective	  inhibitor	  
 
 
Compound Chemical structure Mechanism of action Potency (cultured cells) 
NSC23766 99 
 
Inhibition GEF-Rac1 interaction  
(selective for Tiam1 and Trio) 50 µM 
ITX3 103 
 
 Inhibition GEF-Rac1 interaction  
(selective for Trio) 100 µM 
EHop-016 105 
 
Inhibition GEF-Rac1 interaction  
(selective for Vav2) 1.1 µM 
EHT 1864 106 
 
inhibition of Rac1 nucleotide binding 
(possible allosteric mechanism) ≈5 µM 
Compound 5 100 
 
Inhibition GEF-Rac1 interaction  
(Tiam1) 24.1 µM 
Compound 4 102 
 
Inhibition GEF-Rac1 interaction  
(Tiam1, Trio and Vav2 ) 8.7 µM 
Phox-I1 107 
 
Inhibition effector-Rac1 interaction 
(p67phox) ≈10 µM 
8-OHdG  108 
 
Inhibition of Rac1-dependent  
NADPH oxidase activity ≈156 µM 
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of	   Rac1,	   compound	   NSC23766155.	   This	   small	   molecule	   fits	   into	   the	   surface	  groove	   of	   Rac1	   involved	   in	   the	   binding	  with	   GEFs,	   thus	   interfering	  with	   the	  Tiam1–Rac1	  interaction.	  The	  selective	  action	  of	  NSC23766	  was	  demonstrated	  to	  be	  restricted	  to	  the	  2	  GEFs,	  Trio	  and	  Tiam1,	  without	  interfering	  with	  the	  GEF	  for	  the	  RhoA,	  the	  PDZ-­‐Rho,	  the	  GAP	  Rac1-­‐	  Bcr,	  and	  the	  effector	  PAK1155.	  In	  cell-­‐based	  experiments,	  NSC23766,	  at	  concentration	  of	  50–100	  μM,	  reduced	  Trio-­‐	  or	  Tiam1-­‐mediated	  cell	  growth	  and	  transformation	  without	  a	  significant	  effect	  on	  Vav	   (Rho/	  Rac/Cdc42	  GEF),	  Lbc	   (Rho	  GEF),	  and	   intersectin	   (Cdc-­‐42	  GEF)	  stimulation155.	  A	  more	   specific	   inhibitory	   action	  was	   then	   observed	   for	   the	   compound	   ITX3	  that	  interferes	  with	  Trio	  without	  affecting	  the	  activation	  of	  Rac1	  by	  both	  Tiam1	  and	  Vav2156.	   This	   compound	  was	  derived	   from	  a	  previous	   screening	  of	   3500	  chemical	   entities	   using	   a	   GEF	   activity	   assay156,157.	   In	   a	   cell-­‐based	  pharmacological	   test,	   the	   compound	   ITX3	   inhibited	   the	   formation	   of	   TrioN-­‐dependent	  cell	  structures	  in	  a	  dose-­‐dependent	  manner,	  with	  an	  IC50	  value	  of	  approximately	  100	  μM156.	  The	  most	   potent	  Rac1	   inhibitor	   so	   far	   identified	   is	   the	   compound	  EHop-­‐016,	  with	   an	   IC50	   value	   of	   1.1	   μM,	   approximately	   50-­‐fold	   lower	   than	   that	   of	  NSC23766.	  Ehop-­‐016	  was	  discovered	  by	  optimizing	  the	  chemical	  structure	  of	  NSC23766158;	   however,	   it	   does	   not	   show	   a	   very	   selective	   activity	   on	   Rac1	  because	  it	  also	  acts	  on	  Cdc42.	  Different	  from	  NSC23766,	  Ehop-­‐016	  effectively	  inhibits	  the	  association	  of	  active	  Vav2	  with	  the	  Rac1158.	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Allosteric	  inhibitors	  of	  nucleotide	  binding	  to	  Rac1	  EHT	  1864	   is	   another	   very	   interesting	   compound	   that	   selectively	   reduces	   the	  intracellular	  levels	  of	  Rac1–GTP,	  with	  an	  IC50	  value	  of	  5	  μM.	  The	  biochemical	  analyses	   performed	  with	   recombinant	   Rac1	   found	   that	   EHT	   1864	   possesses	  high-­‐affinity	  binding	  to	  Rac1,	  and	  the	  related	  Rac1b,	  Rac2,	  and	  Rac3	  isoforms,	  and	  this	  association	  promoted	  the	  loss	  of	  bound	  nucleotide,	  placing	  Rac	  in	  an	  inert	  and	  inactive	  state,	  preventing	  its	  engagement	  with	  downstream	  effectors.	  This	  effect	  seems	  to	  be	  the	  result	  of	  an	  inhibitory	  allosteric	  mechanism159.	  
Antagonists	  of	  Rac1-­‐mediated	  NADPH	  oxidase	  activity	  Phox-­‐I1	   is	   the	   most	   recent	   type	   of	   Rac1	   inhibitor	   that	   has	   been	   described.	  Phox-­‐I1	   targets	   the	   interactive	   site	   of	   p67phox	   with	   Rac1	   GTPase	   with	   a	  submicromolar	   affinity	   and	   very	   efficiently	   inhibits	   the	   ROS	   production	   in	  neutro-­‐	   phils	   at	   20	   μM	   concentration160.	   As	   expected,	   a	   similar	   effect	   was	  observed	  with	  compound	  NSC23766	  at	  100	  μM160,	  but	  different	  from	  Phox-­‐I1,	  NSC23766	  also	  abrogated	  the	  phos-­‐phorylated	  PAK	  levels.	  Thus,	  different	  from	  the	   inhibitors	   of	   GEF–Rac	   interaction,	   the	   compound	  Phox-­‐I1	   acts	   selectively	  on	  the	  Rac1-­‐dependnet	  NADPH	  oxidase	  activity.	  The	   8-­‐hydroxy-­‐2-­‐deoxyguanosine	   (8-­‐OHdG)	   represents,	   today,	   the	   only	   Rac1	  inhibitor	   that	   has	   been	   tested	   in	   an	   in	   vivo	   model	   for	   atherosclerosis161.	   8-­‐OHdG	  act	  by	  inhibiting	  the	  ROS	  production	  in	  macrophages	  and	  neutrophils	  by	  blocking	   the	   NADPH	   oxidase	   activity162,163,164,	   and	   a	   similar	   action	   has	   been	  shown	  on	  Ang-­‐II	  and	  PDGF-­‐mediated	  oxidative	  stress	  in	  SMCs.	  The	  effect	  of	  8-­‐OHdG	  (30	  mg/kg21/d21)	  was	   tested	   in	  apoE-­‐/-­‐	  mice	  after	  a	  partial	   ligation	  of	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the	   left	  common	  carotid	  artery165.	  After	  2	  weeks	  of	  treatment,	   the	   lesion	  area	  was	   significantly	   reduced	   in	   treated	   animals	   compared	   with	   vehicle	  (approximately	   60%)	   that	   led	   to	   prevention	   of	   vessel	   lumen	   occlusion.	   This	  protective	   effect	  was	   associated	  with	   reduced	  ROS	   levels	   in	   the	   arterial	  wall	  and	  macrophage	  accumulation.	  In	  vitro	  studies	  also	  documented	  that	  8-­‐OHdG	  inhibits	  SMC	  proliferation	  and	  cell	  adhesion	  molecules	  expression,	  in	  response	  to	  PDGF.	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Small	  animals	  models	  of	  heart	  hypertrophy	  	  The	   study	   of	   heart	   failure	   requires	   viable	   animal	   models	   whereby	   chronic	  changes	   in	  myocardial	  structure	  and	  function	  can	  evolve	  and	  the	  progression	  of	   heart	   failure	   and	   left	   ventricular	   (LV)	   dysfunction	   can	   be	   quantified	  (Table2).	  	  	  
	  
Table2.	  Different	  animal	  models	  for	  hart	  hypertrophy	  and	  heart	  failure	  











RAT$ Left coronary ligation $
$
MI$ •  Availability of multiple modalities to assess 
cardiovascular function $
•  Surgical techniques easier than in mice $
•  Greater quantity of myocardial tissue for postmortem 
analyses $
•  Lower cost than large animal models allows for greater 
“N” $
1. Lack of transgenic or knockout strains$
2. Expense of equipment for cardiovascular physiology 
assessment $










•  Gradual onset hypertension
    Also see above for rat MI model $




Dahl salt-sensitive rat $ Chronic$pressure$overload$$
$
•  No surgery required for heart failure stimulus $
•  Gradual onset hypertension induced by a high-salt diet $
•  Heart failure develops gradually, may be more clinically 
relevant $
•  Also see above for rat MI model $
1. High cost of maintaining colonies for an extended 
period as heart failure develops (6–12 months or more) $










•  No surgery required for heart failure stimulus $
•  Hypertension is more gradual onset. Heart failure, 
therefore, occurs in later stages and thus may be more 
clinically $
•  relevant 
Also see above for rat MI model $
$
1. High cost of maintaining colonies for an extended 
period (6–12 months) $
2. Also see above for rat MI model $
$
MOUSE$ Left coronary ligation $
$
MI$ •  Lower cost than rats 
Ability to assess cardiovascular $
•  physiology using multiple $
•  modalities 
Wide availability of transgenic or $
•  knockout strains of interest including specific cell type or 
inducible transgene expression $
$
1. Significant expertise and expense required for mouse 
surgery or assessment of cardiovascular physiology or 
both $
2. Limited myocardial tissue limits the no. of biochemical 
analyses that can be performed $
1. See above for mouse MI model 
2. Vast overexpression of biologically $











•  See for mouse MI model Potent stimulus for hypertrophy $
•  that develops rapidly thus reducing follow-up time (1–2 
weeks) $
$
1. Hypertension is acute not gradual in onset and thus 
lacks direct clinical relevance $




Muscle lim protein 
knockout $
$
Dilated$cardiomyopathy$$ •  No surgery required for heart failure stimulus $
•  See above for mouse MI model $
$









•  No surgery required for heart failure stimulus $
•  See above for mouse MI model $
$
1. See above for mouse MI model 
2. Vast overexpression of biologically $






Heart$hypertrophy$$ •  Continuous delivery ensures constant compound levels 
in plasma or tissues for maximized therapeutic efficacy 
and reduced adverse effects."
•  The implantion of this pump not require any particular 
expertise."
•  The ability to implant these pumps under the skin with or 
without catheter can minimize the chance of animal 
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Heart	  failure	  in	  rats	  The	   rat	   heart	   failure	   models	   are	   charecterized	   of	   numerous	   potential	  advantages	  inherent	  in	  a	  small	  animal	  model.	  Housing	  and	  maintenance	  costs	  are	  much	  lower	  than	  for	  large	  animals,	  these	  allow	  to	  increase	  the	  number	  of	  animals	  included	  in	  a	  given	  study	  to	  improve	  the	  statistical	  power.	  Moreover,	  more	   recent	   technological	   advances	   in	   echocardiography,	   MRI,	   and	  micromanometer	   conductance	   catheters	   have	   greatly	   streamlined	   the	  assessment	   of	   cardiac	   function	   in	   rodents,	   removing	   a	   significant	   barrier	   to	  their	   use	   in	   heart	   failure	   research.	   The	   development	   of	   suitable	   expertise	   to	  perform	   open-­‐chest	   surgical	   procedures	   and	   invasive	   hemodynamic	  assessments	   in	   rats	   is	   far	   easier	   compared	   with	   that	   required	   for	   mice.	  Additionally,	   investigators	   are	   able	   to	   perform	   a	   greater	   number	   of	  postmortem	   histological	   or	   molecular	   biological	   analyses	   given	   the	  approximately	  10-­‐fold	  greater	  myocardial	  mass	  of	  rats	  compared	  with	  mice.	  
	  
Rat	  models	  of	  myocardial	  injury	  Originally	   myocardial	   infarctions	   in	   rats	   were	   induced	   by	   the	   sequential	  administration	   of	   subcutaneous	   isoproterenol	   causing	   diffuse	   myocardial	  necrosis166.	   Subsequently	   another	   techniques	   was	   developed	   by	   using	   an	  electrocautery	   applied	   to	   the	   epicardial	   surface	   to	   induce	   small,	   focal	  infarctions167.	  	  Finally,	  Pfeffer	  et	  al168	  developed	  the	  rat	  coronary	  ligation	  model	  that	  became	  the	  most	  widely	   used	   heart	   failure	   and	  MI	  model	   in	   the	   decades.	   Infact,	   this	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model	   is	   usefull	   to	   explore	   the	   relationship	   between	   infarct	   size	   and	   LV	  chamber	  dilatation	  and	  function.	  They	  observed	  a	  proportional	  increase	  in	  LV	  volume	   as	   a	   function	   of	   infarct	   size	   that	   was	   a	   highly	   original	   and	   novel	  finding169,	   at	   which	   time,	   the	   notion	   that	   vasodilators	   may	   “unload”	   and	  therefore	  benefit	  failing	  hearts	  was	  gaining	  momentum.	  Angiotensin-­‐converting	   enzyme	   inhibitor,	   captopril,	   therapy	   reduced	   LV	  chamber	  dilation,	  improved	  LV	  systolic	  function,	  and	  increased	  survival	  in	  rats	  with	  moderate	  or	  large	  myocardial	  infarctions170,171.	  This	  innovative	  myocardial	  infarction	  model	  in	  rats	  led	  to	  clinical	  trials	  testing	  the	   utility	   of	   the	   angiotensin-­‐converting	   enzyme	   inhibitor,	   captopril,	   in	   post-­‐miocardial	   infarction	  patients	  with	  reduced	  LV	  function.	  Therefore	  at	  the	  end	  of	  a	  large	  multicenter	  clinical	  trials	  captopril	  decreased	  all-­‐cause	  mortality	  by	  19%	   with	   a	   22%	   reduction	   in	   heart	   failure	   hospitalizations	   after	   a	   mean	  follow-­‐up	  period	  of	  42	  months172.	  The	   reductions	   in	  mortality	   and	  morbidity	  were	   associated	  with	   less	   LV	   dilation	   or	   remodeling	   during	   the	   first	   year	   of	  therapy173,	   this	   is	   a	   clear	   example	   of	   the	   utility	   of	   small-­‐animal	   models	   to	  explore	  new	  and	  potentially	  important	  therapies	  for	  heart	  failure.	  	  Miocardial	   infarction	   model	   was	   also	   essential	   in	   establishing	   the	   beneficial	  effects	   of	   angiotensin	   II	   type	   1	   receptor	   antagonists	   on	   LV	   structure	   and	  function	   following	   miocardial	   infarction174,175.	   However,	   the	   case	   for	  endothelin	   receptor	   antagonists	   illustrates	   that	   results	   in	   this	  model	   are	   not	  necessarily	  mirrored	  in	  clinical	  heart	  failure	  trials.	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Rat	  pressure	  overload	  models	  
Ascending	  aortic	  banding	  The	  ascending	  aortic	  banding	  is	  one	  of	  the	  more	  widely	  used	  surgical	  models	  to	  induce	   pressure	   overload	   in	   rats.	   During	   the	   rats	   growth	   hypertension	  develops	  gradually,	  during	  which	  aortic	  outflow	  is	  increasingly	  impeded.	  Lorell	  and	  colleagues176	  developed	  this	  model	  and	  showed	  that	  8	  weeks	  postbanding,	  rats	   exhibit	   maintenance	   of	   LV	   chamber	   size	   with	   clear	   evidence	   of	   LV	  hypertrophy,	   consistent	   with	   “compensated	   hypertrophy”	   though	   Doppler	  echocardiography	  at	  this	  stage	  shows	  evidence	  of	  increased	  left	  atrial	  pressure.	  18	  weeks,	   overt	   signs	  of	   heart	   failure	  become	  evident	   (ie,	   tachypnea,	   edema,	  pleural	  effusions,	  and	  ascites)	  that	  are	  associated	  with	  LV	  dilation	  and	  systolic	  dysfunction.	  The	  advantages	  and	  disadvantages	  in	  this	  model	  are	  similar	  to	  those	  noted	  for	  the	  rat	  miocardial	  infarction	  model	  with	  the	  added	  benefit	  that	  the	  stimulus	  for	  heart	  failure	  (pressure	  overload)	  is	  gradual	  in	  onset	  as	  is	  the	  progression	  from	  compensated	   hypertrophy	   to	   decompensated	   heart	   failure,	   therefore	  making	  this	  model	  potentially	  more	  clinically	   relevant	   to	  heart	   failure	  progression	   in	  humans.	   Hajjar	   and	   colleagues177,178	   have	   used	   this	   model	   extensively	   to	  explore	  the	  utility	  of	  adenoviral-­‐	  mediated	  gene	  therapy	  to	  restore	  levels	  of	  the	  calcium	  handling	   protein,	   Serca2A,	  whose	   expression	   is	   diminished	   in	   failing	  hearts.	  Once	  optimized	  the	  tecnique	  and	  achieved	  the	  adequate	  myocardial	  expression	  of	   Serca2A	   construct	   wich	   resulted	   in	   a	   clear	   improvements	   in	   LV	   systolic	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function,	   remodeling,	   and	   survival.	   Following	   preclinical	   studies	   in	   larger	  animal	  models,	  this	  novel	  gene	  therapy	  approach	  has	  now	  entered	  the	  clinical	  arena	  as	  a	  phase	  1	  clinical	  trial179.	  
Genetic	  models	  of	  hypertension	  and	  heart	  failure	  in	  rats	  In	  the	  Dahl	  salt-­‐sensitive	  rat,	  hypertension	  and	  heart	  failure	  develop	  gradually	  in	  rats	  placed	  on	  a	  high-­‐salt	  diet.	  LV	  hypertrophy	  without	  chamber	  dilatation	  develops	  within	  4	  to	  6	  weeks	  of	  a	  high-­‐salt	  diet	  followed	  by	  a	  decompensated	  phase	   of	   heart	   failure	   and	   LV	   dilation	   at	   approximately	   15	   to	   20	   weeks180.	  Another	   commonly	   used	   rat	   model	   of	   spontaneously	   hypertensive	   heart	  failure-­‐	  prone	  has	  been	  developed	  by	  McCune	  et	  al181.	  Moreover	  Heyen	  et	  al182	  demonstrated	   that	  progressive	  LV	  hypertrophy	  with	  normal	  ejection	   fraction	  develops	   between	   4	   and	   9	   months	   of	   age;	   by	   12	   months,	   LV	   dilation	   and	  decreased	   LV	   systolic	   function	   occurs	   in	   tandem	   with	   a	   marked	   rise	   in	  circulating	   cytokine	   levels	   including	   tumor	   necrosis	   factor	   TNF-­‐α	   and	  interleukin-­‐6.	  These	   genetic	   models	   of	   pressure	   overload	   and	   heart	   failure	   offer	   several	  advantages.	   Infact	   in	   these	  models	   is	  not	   required	  any	  surgical	   expertise	  and	  moreover	  the	  gradual	  onset	  of	  hypertension	  with	  aging	  has	  more	  direct	  clinical	  relevance,	   with	   both	   models	   being	   characterized	   by	   time-­‐dependent,	  progressive	  LV	  hypertrophy	  in	  the	  early	  stages	  followed	  by	  the	  development	  of	  heart	  failure	  and	  LV	  dysfunction	  in	  later	  stages.	  Genetic	   models	   resulted	   also	   less	   expensive	   for	   the	   cost	   associated	   with	  maintaining	  colonies	  for	  an	  extended	  period	  of	  time	  (6	  to	  12	  months)	  to	  allow	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emergence	  of	  the	  heart	  failure	  phenotype.	  	  
Heart	  failure	  models	  in	  mice	  The	   greatest	   benefit	   in	   using	   mouse	   models	   is	   the	   availability	   of	   a	   great	  number	  of	   relevant	   transgenic	  and	  knockout	   strains.	  The	  advent	  of	   cell	   type-­‐specific,	   inducible	   knockout	   or	   transgenic	   strategies	   has	  made	   the	  mouse	   an	  invaluable	  tool	  to	  study	  the	  pathogenesis	  of	  heart	  failure	  and	  to	  identify	  novel	  therapeutic	  targets	  with	  lower	  housing	  costs	  compared	  with	  rats.	  In	  addiction	  cardiac	   physiological	   assessments	   have	   been	   facilitated	   greatly	   by	   newer	  technologies	  such	  as	  ultrahigh	  resolution	  ultrasound183	  and	  micromanometer	  conductance	   technology	   for	   pressure	   volume	   loop	   analyses184,185.	   However,	  these	   new	   methods	   are	   very	   expensive	   and	   pose	   significant	   technical	  challenges	   to	   laboratories	  without	   an	   appropriate	   expertise.	  Whereas	   the	   rat	  models	   listed	   above	   have	   been	   used	   extensively	   to	   explore	   the	   potential	   for	  novel	  pharmacological	  or	  molecular	  agents	   for	   the	   treatment	  of	  heart	   failure,	  mouse	  models	  are	  best	  used	  as	  “proof	  of	  principle”	  to	  identify	  important	  gene	  or	  protein	  targets	  that	  pave	  the	  way	  for	  the	  development	  of	  new	  molecular	  or	  pharmacological	  therapies.	  	  
Mouse	  models	  of	  myocardial	  injury	  The	  denvelopment	  of	  transgenic	  and	  knockout	  mouse	  models	  determined	  new	  important	   approaches	   to	   study	   disease	   and	   therefore	   the	   development	   of	  surgically	   induced	  mouse	  models	  of	  heart	   failure	  became	  necessary.	  30	  years	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ago	  was	  described	  a	  first	  mouse	  model	  of	  coronary	  ligation.	  Recently	   	   Michael	   et	   al186.	   Estabilished	   a	   first	   mouse	   model	   of	   ischemia-­‐reperfusion	   injury.	   In	   this	   model	   they	   identified	   that	   mouse	   left	   coronary	  anatomy	   is	   highly	   variable.	   Porter	   et	   al.	   developed	   a	   model	   of	   permanent	  coronary	   ligation	   in	   mice	   and	   others	   effort	   to	   gain	   further	   insight	   into	  pathophysiology	  of	  post-­‐miocardial	  infarction	  cardiac	  remodeling187,188.	  Mouse	  models	  of	  heart	  failure	  can	  be	  used	  to	  identify	  potentially	  important	  and	  novel	  targets	  for	  pharmacological	  or	  molecular	  therapy.	  	  Many	   studies	   with	   overexpression	   or	   KO	   of	   proteins	   (ie,	   CaMKII)	   exemplify	  how	  mouse	  models	   can	  unveil	   the	   physiological	   relevance	   of	   a	   given	  protein	  using	   complementary	   overexpression	   and	   molecular	   and	   pharmacological	  strategies.	  	  	  
Mouse	  pressure	  overload	  model	  of	  transverse	  aortic	  constriction	  The	  transverse	  aortic	  constriction	  (TAC)	  model	  is	  the	  most	  widely	  used	  model;	  it	  was	   first	   described	  by	  Rockman	   et	   al.189,190.	   The	   greatest	   advantage	   of	   this	  model	   is	   the	   ability	   to	   quantify	   the	   pressure	   gradient	   across	   the	   aortic	  structure	   that	   allows	   stratification	   of	   LV	   hypertrophy.	   The	   sudden	   onset	   of	  hypertension	  achieved	  with	  TAC	  causes	  an	  approximately	  50%	  increase	  in	  LV	  mass	  within	   2	  weeks,	  making	   this	  model	   an	   excellent	   choice	   to	   examine	   the	  utility	   of	   pharmacological	   or	   molecular	   interventions	   that	   may	   limit	  hypertrophy.	  An	   important	   drawback	   of	   the	   TAC	   model	   is	   the	   variability	   in	   the	   LV	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remodeling	   responses	   among	   different	  mouse	   strains:	   C57BL6	  mice	   develop	  rapid	  LV	  dilation191	  after	  TAC	  that	  may	  not	  occur	  with	  other	  strains.	  Another	  important	  aspect	   is	  that	  the	  acute	  onset	  of	  severe	  hypertension	  characteristic	  of	  this	  model	  lacks	  direct	  clinical	  relevance.	  	  
Genetic	  models	  of	  dilated	  cardiomyopathy	  in	  mice	  Numerous	  KO	  or	  transgenic	  mice	  have	  been	  developed	  that	  have	  implicated	  a	  given	  protein	  in	  the	  pathogenesis	  of	  heart	  failure	  and	  dilated	  cardiomyopathy.	  Arber	   et	   al192	   developed	   a	   model	   of	   dilated	   cardiomyopathy	   in	   which	  homozygous	  deletion	  of	  the	  gene	  encoding	  muscle	  lim	  protein	  caused	  myofiber	  disarray,	  LV	  hypertrophy,	  dilation,	  systolic	  dysfunction,	  and	  heart	  failure.	  Muscle	   lim	   protein	   is	   an	   actin-­‐based	   cytoskeletal	   protein	   that	   positively	  regulates	   myogenic	   differentiation.	   The	   authors	   hypothesized	   that	   its	  disruption	   may	   uncouple	   mechanical	   load	   from	   the	   induction	   of	   muscle-­‐specific	   genes	   that	   maintain	   striated	   muscle	   function.	   Indeed,	   muscle	   lim	  protein	   knockout	   mice	   develop	   a	   cardiac	   phenotype	   resembling	   dilated	  cardiomyopathy	   characterized	   by	   the	   development	   of	   LV	   dysfunction,	   heart	  failure,	   and	   death.	  Muscle	   lim	   protein	   knockout	  mice	   have	   since	   served	   as	   a	  genetic	   model	   of	   heart	   failure	   that	   is	   used	   by	   many	   laboratories	   to	   explore	  molecular	   therapies	   that	   might	   “rescue”	   the	   heart	   failure	   and	   dilated	  cardiomyopathic	  phenotype.	  Another	   example	   of	   dilated	   cardiomyopathy	   was	   the	   TNF-­‐α	   overexpressing	  mice.	   In	   this	   model	   mice	   develop	   LV	   hypertrophy,	   dilatation,	   and	   profound	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systolic	  dysfunction	  associated	  with	  heart	  failure	  and	  premature	  death193.	  Treating	   	   these	  mice	  with	  a	  soluble	  chimeric	  protein	  comprised	  of	   the	  TNF-­‐α	  receptor	  bound	  to	  an	  IgG	  fragment	  neutralizes	  circulating	  TNF-­‐α	  and	  improves	  indices	  of	  cardiac	  function	  in	  these	  mice194,195.	  	  Howerver	  the	  positive	  effects	  of	  soluble	  TNF	  receptor	  chimera	  viewed	  in	  mice	  models	  didn’t	   offer	  no	  morbidity	   or	  mortality	  benefits	   to	  patients	  with	  heart	  failure	   and	   LV	   systolic	   dysfunction,	   illustrating	   that	   positive	   results	   in	  preclinical	  rodent	  studies	  do	  not	  necessarily	  translate	  to	  clinical	  benefits	  when	  applied	  to	  heterogeneous	  heart	  failure	  populations.	  	  
Mouse	  models	  of	  heart	  hypertrophy	  induced	  by	  Angiotensin	  II	  A	  model	  of	  heart	  hypertrophy	  in	  mice	  was	  developed	  by	  a	  continuous	  infusion	  of	  angiotensin	  II	  by	  means	  of	  an	  osmotic	  pump	  leading	  to	  sustained	  increased	  of	   systolic	   blood	  pressure.	  This	  model	   causes	   an	   eccentric	  hypertrophy,	  with	  increasing	   left	   ventricle	   mass	   and	   cardiomyocyte	   cross-­‐sectional	   areas	   and	  reduction	  of	  ejection	  fraction.	  	  Ang	   II	   treatment	   increase	   the	   production	   of	   O.-­‐	   of	   3.3	   fold	   in	   cardiac	   tissues	  respect	  WT,	  this	  increasing	  is	  in	  accordance	  with	  the	  improvement	  of	  NADPH	  oxidase	   activity	   is	   incresed	   of	   1.9	   fold.	   Moreover	   in	   these	   mice	   there	   is	   an	  increase	  of	  cardiac	  fetal	  gene	  expression,	  in	  particular,	  ANF	  and	  BNP.	  With	  this	  model	  Liao	  et	  al.196	  demontrated	  how	  NADPH	  oxidase	  plays	  a	  critical	  role	   in	   the	   development	   of	   cardiac	   hypertrophy	   in	   response	   to	   Ang	   II,	   in	  particular	  the	  small	  G	  protein	  Rac1	  through	  interaction	  with	  gp91phox	  and	  the	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In	   the	   last	   decade,	   the	   small	   GTPase	   protein	   Rac	   has	   gained	   increasing	  attention	  for	  its	  role	  in	  cardiovascular	  diseases.	  Transgenic	  mice	  expressing	  a	  constitutively	   activated	   Rac1	   mutant	   in	   the	   myocardium	   developed	   either	   a	  lethal	   cardiac	   dilated	   phenotype	   or	   a	   transient	   cardiac	   hypertrophy	   that	  resolved	   with	   age197.	   In	   line	   with	   this	   evidence,	   cardiomyocyte	   knock-­‐out	  specific	   mice	   for	   Rac1	   are	   resistant	   to	   cardiac	   hypertrophy	   induced	   by	  angiotensin	   infusion198.	   The	   role	   of	   Rac1	   in	   cardiac	   function	   has	   been	  associated	   with	   its	   regulatory	   function	   on	   the	   NADPH	   activity	   and	   thus	  generation	   of	   reactive	   oxygen	   species198.	   Moreover,	   endothelial	   Rac1	  haploinsufficient	   mice	   showed	   decreased	   expression	   and	   activity	   of	   eNOS,	  which	  correlated	  with	  the	  decrease	  in	  endothelium-­‐dependent	  vasorelaxation	  and	   caused	  mild	   hypertension199.	   This	   evidence	   suggests	   a	   protective	   role	   of	  Rac1	   in	   endothelial	   cells	   and	   more	   in	   general	   in	   vascular	   diseases.	   Various	  agonists	   and	  extracellular	  matrices	  appear	   to	  be	   required	   for	   a	  proper	  Rac1-­‐mediated	   modulation	   of	   endothelial	   barrier	   properties,	   through	   the	  involvement	   of	   reactive	   oxygen	   species	   and	   the	   actin	   cytoskeleton200–202.	  However,	   Rac1	   directly	   regulates	  many	   other	   cellular	   events	   associated	  with	  the	   development	   of	   atherosclerotic	   plaque,	   including	   smooth	   muscle	   cell	  migration203	  and	  proliferation204,	  and	  leukocyte–endothelial	  cell	  interaction205.	  Thus,	   the	   final	   outcome	  of	   the	   role	   of	  Rac1	   in	   cardiovascular	   diseases	   is	   still	  controversial.	  Nevertheless,	  pathway-­‐based	  genome-­‐wide	  association	  analysis	  of	  coronary	  heart	  disease	  (CHD)	  has	  identified	  Rac1	  as	  one	  of	  the	  biologically	  important	   genes	   in	   CHD,	   thus	   indicating	   that	   Rac	   represents	   a	   possible	   new	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pharmacological	   target	   for	   cardiovascular	   diseases206.	   Thus	   from	   these	  evidence	   it	   appears	   clear	   that	   Rac1	   represents	   a	   new	   potential	  pharmacological	  target	  for	  cardiovascular	  disease.	  	  The	  purpose	  of	  the	  present	  study	  was	  to	  identify	  new	  and	  more	  active	  chemical	  entities	   capable	   to	   inhibit	   in	   a	   selective	   manner	   the	   Rac1	   activity,	   and	   then	  study	  their	  effects	  in	  in	  vitro	  experimental	  	  models.	  	  For	  the	  	  identification	  of	  	  new	  comopounds,	  in	  collaborations	  with	  Dott.	  Contini	  at	   the	   University	   of	   Milan,	   two	   approaches	   has	   been	   followed:	   1)	   a	   virtual	  screening	  approach	  and	  2)	  a	  computer	  aided	  de-­‐novo	  design	  of	  a	  new	  scaffold,	  starting	  from	  the	  previously	  described	  3D	  model	  of	  the	  complex	  between	  Rac1	  and	  NSC23766	  (see	  material	  and	  methods).	  The	   identified	   compounds	   have	   been	   then	   screened	   in	   in	   vitro	   experimental	  model	   for	   their	   inhibitory	  activity	  on	  Rac	  and	  RhoA	  activation	   in	  response	   to	  PDGF-­‐BB.	  The	  most	  promising	  compound	  were	  then	  utilized	  for	  the	  evaluation	  of	  their	  effect	  on	  cell	  migration	  and	  cell	  adhesion,	  Rac-­‐mediated	  cellular	  events.	  	  A	   second	   step	   of	   the	   present	   research	   project	   was	   then	   the	   analysis	   of	   the	  pharmacokinetic	  and	  pharmacodynamic	  profile	  of	   the	  Rac	   inhibitor	   identified	  and	  the	  development	  of	  an	  in	  vivo	  model	  of	  heart	  hypertrophy.	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Virtual	  screening	  approach	  The	  first	  inhibitor	  of	  Rac	  protein	  discovered	  was	  compound	  NSC23766	  capable	  to	   interfere	  with	  the	   interaction	  between	  Rac	  and	   its	  activator	  GEF	   inhibiting	  its	   activation.	   This	   compound	   shows	   the	   capacity	   to	   inhibit	   Rac	   activity	   in	   a	  selective	  manner	  without	   affecting	   the	   activity	   of	   RhoA	   and	  Cdc42.	  However	  this	   compound	   resulted	   not	   very	   powerful	   with	   an	   IC50	   of	   50μM,	   moreover	  compound	  NSC23766	  is	  not	  characterized	  by	  drug-­‐like	  structure.	  Starting	  from	  compound	  NSC23766	  in	  our	  laboratory	  was	  denveloped	  another	  classes	  of	  rac	  inhibitors	  with	  the	  same	  mechanisms	  of	  action.	  In	  particular	  was	  found	  compounds	  4	  and	  5	  more	  active	  than	  compound	  NSC23766	  with	  an	  IC50	  of	  	  24.1	  and	  12.2μM	  respectively207.	  Starting	   from	  this	  work	   the	  aim	  of	  our	  study	  was	   to	   identify	  new	  potent	  and	  selective	  compound	  capable	  to	  inhibit	  the	  Rac	  protein	  activation.	  From	  the	  hit	  compounds	  4	  and	  5207,	  a	  similarity	  search	  was	  performed	  directly	  on	  the	  ZINC	  DB	  website208.	  The	  clustering	  and	  search	  algorithms	  implemented	  in	  ZINC	  are	  based	  on	  a	  search	  engine	  provided	  by	  ChemAxon	  where	  both	  the	  query	   and	   molecules	   in	   the	   DB	   are	   represented	   by	   finger-­‐prints,	   and	   the	  similarity	  degree	  is	  expressed	  as	  a	  Tanimoto	  coefficient	  (TC).	  All	  the	  molecules	  with	  a	  TC	  value	  of	  	  ≥	  0.85	  with	  respect	  to	  either	  compounds	  1	  (53	   derivatives)	   or	  2	   (117	   derivatives)	   were	   selected	   for	  molecular	   docking	  evaluation.	  As	  the	  receptor,	  the	  previously	  derived	  3D	  model207	  was	  used	  and	  a	  consensus	  docking	  strategy	  using	  two	  different	  softwares,	  MOE	  and	  AutoDock4	  (AD4)209,	   and	   a	   total	   of	   three	   scoring	   functions	   (London	   dG	   and	   affinity,	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implemented	  in	  MOE,	  and	  the	  default	  AD4	  scoring	  function)	  was	  adopted	  as	  it	  proved	   to	   be	   a	   rather	   successful	   screening	   strategy207.	   Energies	   obtained	   by	  MOE	   and	  AD4	   virtual	   screenings	  were	   compared	   and	   only	   those	   compounds	  for	   which	   the	   computed	   docking	   energies	   resulted	   above	   the	   defined	  thresholds	   (affinity	   <	   -­‐4.5,	   London	  dG	  <	   -­‐7.0,	  AD4	  binding	   energy	  <	   -­‐6.5	   kcal	  mol-­‐1)	  were	  selected.	  Within	  this	  selection,	  a	  total	  of	  57	  commercially	  available	  N-­‐	   (sulfamoylaryl)arylamides	   with	   differences	   in	   regions	   1	   and	   2	   (Figure5)	  were	  selected	  and	  acquired	  for	  biochemical	  testing.	  	  
	  
Figure	   5:	   General	   chemical	   structure	   of	   new	   Rac	   inhibitors.	   Chemical	  modifications	  of	  the	  two	  indicated	  regions	  ledto	  the	  identification	  of	  a	  total	  of	  57	   commercially	   available	   N-­‐(sulphamoylaryl)	   arylamides	   selected	   and	  acquired	  for	  biochemical	  testing.	  	  
Design	   and	   synthesis	   of	   arylsubstituted	   2-­‐amino-­‐3-­‐
(phenylsulfanyl)norbornane-­‐2-­‐carboxylates	   as	   rac1-­‐tiam1	   protein-­‐

















Region 1 Region 2 
	   60	  
amino-­‐3-­‐(phenylsulfanyl)norbornane-­‐2-­‐carboxylate	   scaffold	  were	   synthetized	  for	  the	  pharmacological	  tests.	  	  The	   use	   of	   the	   2-­‐amino-­‐3-­‐(phenylsulfanyl)norbornane-­‐2-­‐carboxylate	   scaffold	  for	   the	  design	  of	  potent	  and	   innovative	  Rac1	   inhibitors	  acting	  at	   the	  protein-­‐protein	  interaction	  interface	  between	  Rac1	  and	  Tiam1	  has	  been	  investigated.	  A	  binding	  mode	  analysis	  has	  been	  performed	  by	  docking	  followed	  by	  molecular	  dynamic	   simulations	  and	  MM-­‐GBSA	  analysis,	   confirming	   that	   the	  norbornane	  scaffold	   can	   be	   conveniently	   used	   to	   prepare	   potent	   and	   selective	   Rac1	  inhibitors210.	  	  
Compounds.	  	  Compounds	  selected	  from	  the	  virtual	  screening	  procedure	  were	  acquired	  from	  either	   Enamine	   (http://www.enamine.net/)	   or	   InterBioScreen	  (http://www.ibscreen.com/)	  and	  were	  guaranteed	  pure	  at	  95%	  by	  both	  NMR	  and	  LC-­‐MS	  analyses.	  The	  purity	  of	  compounds	  1-­‐25	  was	  also	  verified	  by	  HPLC	  analysis	  and	  resulted	  above	  98%	  (stationary	  phase	  Ascentis	  SI	  Supelco.	  3	  μm.	  4.6	  x	  150.0	  mm;	  mobile	  phase.	  n-­‐hexane/ethanol	  70:30;	  flow	  rate	  0.7mL/min;	  detection	  UV	  254.	  270	  and	  290	  nm).	  Chemical	   compounds	  were	  dissolved	   in	  DMSO	  to	  10	  mM	  final	  concentration	  and	  stored	  at	  4	  °C.	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Reagents	  and	  antibodies.	  DMEM,	   trypsin-­‐EDTA,	   penicillin,	   streptomycin,	   non-­‐essential	   amino	   acid	  solution,	  fetal	  calf	  serum	  (FCS),	  disposable	  culture	  flasks	  and	  petri	  dishes	  were	  purchased	   from	  Euroclone	   S.p.A.	   (Pero,	  Milan,	   Italy).	   Platelet	   derived	   growth	  factor-­‐BB	  (PDGF-­‐BB)	  was	  purchased	  from	  tebu-­‐bio	  s.r.l.	  (Magenta,	  Milan,	  Italy).	  For	   western	   blot	   analysis,	   the	   following	   antibodies	   were	   used:	   mouse	  monoclonal	   anti-­‐Rac1	   (clone	   23A8,	   Upstate),	   anti-­‐mouse	   peroxidase-­‐	  conjugated	   secondary	   antibodies	   (Jackson	   ImmunoResearch	   Lab;	  Cambridgeshire,	   UK).	   FITC-­‐phalloidin	   was	   purchased	   from	   Sigma	   Aldrich	  (Milan,	  Italy).	  
	  
Cell	  culture.	  Human	  SMCs	  (A617	  from	  human	  femoral	  artery)	  were	  grown	  in	  monolayers	  at	  37	   °C	   in	   a	   humidified	   atmosphere	   of	   5%	   CO2	   in	   DMEM	   supplemented	   with	  10%	  (v:v)	  fetal	  calf	  serum	  (FCS),	  100	  U/ml	  penicillin,	  0.1	  mg/ml	  streptomycin	  and	   non-­‐essential	   amino	   acids.	   The	   medium	   was	   changed	   every	   third	   day.	  SMCs	  were	  identified	  for	  growth	  behavior,	  morphology	  and	  using	  monoclonal	  antibody	   specific	   for	   α-­‐actin,	   the	   actin	   isoform	   typical	   of	   SMC.	   For	   the	  experiments	   cells	   were	   seeded	   at	   a	   density	   of	   2x105/35	  mm	   petri	   dish	   and	  incubated	  with	   DMEM	   supplemented	  with	   10%	   FCS;	   24	   h	   later	   the	  medium	  was	  changed	  to	  one	  containing	  0.4%	  FCS,	  and	  the	  cultures	  were	  incubated	  for	  48	  h.	  At	  this	  time,	  the	  compounds	  were	  added	  to	  the	  cultured	  media	  and	  after	  4	  hours	  G-­‐LISA	  assays	  or	  cell	  adhesion	  assay	  was	  performed.	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RNA	  preparation	  and	  quantitative	  real	  time	  PCR	  analysis.	  Total	  RNA	  was	  prepared	   from	  mouse	  heart	   tissues	  extracted	  with	  Macherey-­‐Nagel	   DNA,	   RNA	   and	   protein	   purification	   kit	   according	   to	   manufacturer’s	  instructions.	   For	   quantitative	   real	   time	   PCR	   reaction	   reverse	   transcription-­‐polymerase	   first-­‐strand	   cDNA	   synthesis	  were	   performed	  with	   0.5	   μg	   of	   total	  RNA,	  using	  iScriptTM	  cDNA	  synthesis	  Kit	  (BIO-­‐RAD	  Laboratories,	  Hercules,	  CA,	  USA).	  Real	  time	  PCR	  were	  then	  performed	  using	  the	  Sybr	  Green	  QPCR	  Master	  Mix	   (Carlo	  Erba)	   and	  ABI	  Prism®	  7000	  Sequence	  Detection	  System	   (Applied	  Biosystems,	  Monza,	   Italy).	  mRNA	   expression	   levels	   of	   ANF	   (atrial	   natriuretic	  peptide),	  BNP	  (brain	  natriuretic	  peptide)	  and	  SMA	  (skeletal	  muscle	  actin)	  were	  normalized	   by	   using	   ribosomal	   18S	   rRNA.	   PCR	   cycling	   conditions	   were	   as	  follows:	  94°C	  for	  3	  minutes,	  40	  cycles	  at	  94°C	  for	  15	  s,	  and	  60°C	  for	  1	  min.	  Data	  were	  expressed	  as	  Ct	  values	  and	  used	  for	  the	  relative	  quantification	  of	  targets	  with	  the	  ΔΔCt	  calculation.	  The	  primers	  utilized	  were	  the	  following:	  mANF	  Forward:	  5’-­‐AGGAGAAGATGCCGGTAGAAGA-­‐3’	  mANF	  Reverse:	  5’-­‐GCTTCCTCAGTCTGCTCACTCA-­‐3’	  	  mBNP	  Forward:	  5’-­‐AGGGAGAACACGGCATCATT-­‐3’	  mBNPR	  Reverse:	  5’ACAGCACCTTCAGGAGATCCA-­‐3’	  	  α-­‐SMA	  Forward:	  5’-­‐TGTGCGCGACATCAAAGAG-­‐3’	  α-­‐SMA	  Rev	  Reverse:	  5’-­‐GTGGCCATCTCATTCTCGAAA-­‐3’	  	  
	  
Cell	  migration	  assay.	  The	  Boyden	  chamber	  and	  the	  polycarbonate	  membrane	  were	  purchased	  from	  Biomap	  (Agrate	  Brianza,	  Milan	  Italy).	  The	  membranes	  were	  coated	  with	  a	  0.1	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mg/ml	   of	   type	   I	   collagen	   solution	   (PureCol®,	   Nutacon	   BV,	   Leimuiden,	   The	  Netherlands)	   in	   0.1	  mol/L	   of	   acetic	   acid	   at	   37°C	   for	   24	   h	   and	  washing	   twice	  with	   DMEM	   before	   cell	   seeding.	   The	   lower	   compartments	   of	   the	   wells	   of	   a	  modified	   Boyden	   chamber	   were	   filled	   (in	   triplicate)	   with	   DMEM	   containing	  0.4%	   FCS	   in	   the	   absence	   or	   presence	   of	   PDGF-­‐BB	   (20	   ng/ml),	   whereas	   the	  upper	   compartments	   were	   filled	   with	   aliquots	   of	   the	   SMCs	   suspensions	  containing	   106	   cells/ml.	   The	   chamber	   was	   incubated	   at	   37°C	   for	   6	   h.	   The	  membrane	   was	   then	   carefully	   removed.	   Adherent	   SMCs	   on	   the	   top	   were	  eliminated	   and	   the	   membrane	   was	   stained	   with	   the	   Diff-­‐Quik	   staining	   set	  (Biomap,	  Agrate	  Brianza,	  Milan	  Italy).	  The	  number	  of	  transmigrated	  cells	  was	  then	   counted	   in	   four	   random	   high-­‐power	   fields	   (HPFs)	   under	   high	  magnification	   (objective	   lens	  20x).	  Data	  were	  presented	  as	  mean	  ±	  SD	  of	   the	  counted	  cells	  in	  triplicate	  wells.	  
	  
Video	  microscopy	  analysis.	  Time-­‐lapse	   video	  microscopy	   was	   performed	   as	   described	   previously,65,	   66	  with	  slight	  modifications.	   In	  brief,	   cultured	  SMCs	  were	  placed	  on	  the	  stage	  of	  an	   inverted	   motorized	   microscope	   (Axiovert	   200M	   Zeiss	   Instr.,	   Oberkochen,	  Germany)	   in	   a	   cage	   incubator	   (CTI	   Controller	   2700	   digital	   Zeiss	   Instr.,	  Oberkochen,	   Germany)	   at	   37°C.	   Phase-­‐contrast	   images	  were	   collected	  with	   a	  10x	  A-­‐Plan	   lens	  (Zeiss	   Instr.,	  Oberkochen,	  Germany)	  every	  15	  minutes	  over	  a	  16-­‐h	   period	   using	   a	   camera	   (AxioCam	   HRm,	   Zeiss	   Instr.,	   Oberkochen,	  Germany)	  and	  the	  Axiovision	  LE	  software	  (Zeiss	  Instr.,	  Oberkochen,	  Germany).	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Videos	   were	   generated	   using	   the	   ImageJ	   software	   for	   image	   analysis.	   Cell	  trajectories	   were	   determined	   using	   the	   manual	   tracking	   plugin	   of	   ImageJ	  (http://rsbweb.nih.gov/ij/download.html).	  This	  procedure	   generated	   x	   and	  y	  coordinates	   for	   the	   center	   of	   each	   cell	   at	   each	   time	   point.	   Trajectories	  were	  reconstructed	   according	   to	   the	   recorded	   data.	   The	   distance	   covered	   by	   each	  cell	   was	   extracted	   from	   the	   track	   plots.	   Ten	   cells	   from	   three	   independent	  experiments	   were	   analyzed	   for	   each	   condition,	   and	   data	   were	   expressed	   as	  mean	  ±	  SD.	  	  
G-­‐LISA	  assay	  for	  Rac1	  and	  RhoA.	  The	   intracellular	   amount	   of	   Rac1-­‐GTP	   and	   RhoA-­‐GTP	   were	   determined	   by	  using	  the	  G-­‐LISA	  assay	  (Cytoskeleton,	  Inc	  Denver,	  CO,	  USA).	  The	  GLISA™	  assay	  uses	   a	   96-­‐well	   plate	   coated	   with	   RBD	   domain	   of	   either	   RhoA	   or	   Rac1.	   The	  active	  GTP-­‐bound	   form	  of	  Rho	  protein,	  but	  not	   the	   inactive	  GDP-­‐bound	   form,	  from	  a	   total	   cell	   lysates	   of	   human	   cells,	   binds	   to	   the	  plate.	  Bound	  active	  Rho	  protein	   was	   then	   detected	   by	   incubation	   with	   a	   specific	   primary	   antibody	  followed	  by	  a	  secondary	  antibody	  conjugated	  to	  horseradish	  peroxidase	  (HRP).	  The	  signal	  is	  then	  developed	  with	  OPD	  reagents.	  	  
Cytoskeleton	  staining.	  Cells	   were	   fixed	   in	   4%	   paraformaldehyde	   at	   room	   temperature	   for	   10	   min,	  permeabilized	  in	  0.1%	  Triton	  X-­‐100	  in	  PBS	  for	  5	  min,	  and	  incubated	  with	  FITC-­‐phalloidin	   (Molecular	   Probes).	   Cells	   were	   then	  washed	   four	   times	  with	   PBS,	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incubated	   with	   DAPI	   solution	   for	   5	   min,	   and	   coverslipped	   with	   vectashield	  mounting	   media.	   Cytoskeleton	   staining	   of	   cells	   was	   analyzed	   by	   fluorescent	  microscope.	  	  
Cell	  adhesion	  assay.	  	  Adhesion	   studies	   were	   performed	   as	   described	   previously211.	   Briefly,	   SMCs	  were	   harvested	   with	   Trypsin-­‐EDTA	   after	   4h	   incubation	   with	   increasing	  concentrations	   of	   tested	   compounds,	   centrifuged	   and	   resuspended	   in	   DMEM	  with	   0.4%	   FCS	   and	   plated	   into	   96	   well/plates	   at	   100,000	   cells/well.	   Plates	  were	   incubated	   for	   15	   min	   at	   37	   °C	   in	   the	   incubator,	   and	   the	   assay	   was	  terminated	   by	   rinsing	   the	   plates	   with	   PBS	   and	   fixing	   the	   cells	   with	   4%	  paraformaldehyde.	  Cells	  were	  stained	  with	  0.5%	  toluidine	  blue	  for	  1	  min	  and	  rinsed	   in	   water.	   They	   were	   then	   solubilized	   by	   the	   addition	   of	   1%	   SDS	   and	  quantitated	  in	  a	  microtiter	  plate	  reader	  at	  595	  nm.	  
	  
Western	  blot	  analysis.	  	  Cells	  were	   lysed	  with	   a	   solution	   of	   50	  mM	  Tris	   pH	   7.5,	   150	  mM	  NaCl,	   0.5%	  Nonidet-­‐P40,	  containing	  a	  protease	  and	  phosphatase	  inhibitor	  cocktails	  (Sigma	  Aldrich,	  Milan,	  Italy).	  Equal	  amount	  of	  total	  protein	  per	  sample	  were	  separated	  by	  SDS-­‐PAGE	  under	  reducing	  conditions,	   transferred	  to	   Immobilon	  PVDF	  (GE	  Healthcare	   Little	   Chalfont,	   Buckinghamshire,	   UK)	   and	   subsequently	  immunoblotted	   with	   antibody	   anti	   Rac1	   (Clone	   23A8,	   Millipore)	   following	  appropriate	   secondary	   antibody,	   prior	   to	   visualization	   by	   enhanced	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chemiluminescence	   (LiteAblot	   Extend	   Long	   Lasting	   Chemiluminescent	  Substrate,	  EuroClone)212.	  
	  
Transfection	  of	  siRNA.	  	  The	   siRNAs	  directed	   to	  Rac1	  was	   from	  Ambion	   life	   technologiesTM	   (Silencer	  Select	   Pre-­‐designed	   siRNAs)203.	   Transfections	   were	   performed	   using	  siLentFectTM	   Lipid	   Reagent.	   (BIO-­‐RAD	   laboratories,	   Hercules,	   CA,	   USA)	  according	  to	  the	  manufacturer’s	  protocol213.	  SMCs	  were	  seeded	  at	  a	  density	  of	  2×105/Petri	  dish	  (35	  mm)	  the	  day	  before	  the	  transfection	  in	  10%	  FCS	  DMEM.	  Cells	  were	   then	   transfected	  with	   20	   nM	   of	   siRNA	   for	   24	   h	   then	   the	  medium	  replaced	   with	   DMEM	   containing	   0.4%	   FCS	   for	   an	   additional	   24	   h	   before	  performing	  the	  adhesion	  assay	  assay.	  
	  
Transfection	  of	  plasmid	  encoding	  GEFs.	  	  Tiam1	  vector	  was	  kindly	  provided	  by	  J.	  Collard	  (Cancer	  Institute,	  Amsterdam,	  The	   Netherlands);	   TrioN	   vector	   was	   from	   P.	   Fort	   (Centre	   de	   Recherche	   de	  Biochimie	  Macromoléculaire,	  Universités	  Montpellier	  I	  et	  II,	  France)	  and	  Vav2	  vector	   from	   X.	   Bustelo	   (Centro	   de	   Investigación	   del	   Cáncer-­‐Cancer	   Research	  Center,	   CSIC-­‐University	   of	   Salamanca,	   Spain).	   Transfections	   were	   performed	  using	   jetPEI	   transfection	   reagent	   (Polypus-­‐transfection	   SA,	   Illkirch,	   France)	  according	   to	   the	  manufacturer’s	   protocol.	   SMCs	  were	   seeded	   at	   a	   density	   of	  2×105/Petri	  dish	  (35	  mm)	  the	  day	  before	  the	  transfection	  in	  10%	  FCS	  DMEM.	  Cells	  were	   then	   transfected	   for	   24	   h	   then	   the	  medium	   replaced	  with	   DMEM	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containing	   0.4%	   FCS	   for	   an	   additional	   24	   h.	   Cells	   were	   then	   incubated	  with	  compound	  2	  and	  Rac-­‐GTP	  levels	  determined	  by	  G-­‐LISA	  assay	  after	  4	  h.	  
	  
Statistical	  analysis.	  	  All	  data	  shown	  are	  representative	  of	  at	  least	  three	  replicate	  experiments.	  Data	  are	   expressed	   as	   mean±SD.	   Statistical	   analyses	   were	   performed	   using	   the	  unpaired	   Student’s	   T	   test.	   P	   values	   <0.05	   were	   considered	   significant.	   The	  concentration	  of	  compounds	  required	  to	   inhibit	  50%	  of	  Rac-­‐GTP	  intracellular	  levels	   (IC50)	   was	   calculated	   by	   nonlinear	   regression	   curve	   (SigmaPlot	  software;	  Systat	  Software,	  Inc.,	  Point	  Richmond,CA).	  
	  
Determination	  of	  plasma	  levels	  of	  Rac	  inhibitor	  compound	  4.	  For	  the	  pharmacokinetics	  analysis	  was	  used	  as	  a	  stationary	  phase	  C18	  column	  of	   15cm	   and	   a	  mobile	   phase	   consisting	   of	   a	  mixture	   of	   A	   99,9%	  of	  H2O	   and	  0,1%	   ammonium	   formate	   and	   one	   of	   B	   of	   99,9	   %	   acetonitrile	   and	   0,1%	   of	  mixture	  A.	  The	  two	  solutions	  were	  then	  mixed	  with	  the	  following	  gradient	  protocol:	  
• Time	  0:	  90%	  A	  +	  10%B	  
• 6	  min:	  10%	  A	  +	  90%	  B	  
• 10	  min:	  2%	  A	  +	  98%	  B	  
• 15	  min:	  2%	  A	  +	  98%	  B	  
• 15.10	  min:	  90%	  A	  +	  10%	  B	  Final	  Time:	  30	  min.	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Flux:	  0,25	  mL/min	  Before	   performing	   the	   experiment	   on	   plasma	   samples	   we	   performed	   the	  construction	  of	  the	  standard	  scale	  melting	  at	  concentrations	  of	  0.3125,	  0.625,	  1.25,	  2.5	  and	  5ng	  of	  compound	  4	  in	  acetone	  (Figure6).	  	  
	  	  
Figure	   6:	  Evaluation	   of	   the	   compound	   4	   with	   known	   concentrations	   of	  
human	   plasma.	   The	   plasma	   was	   prepared	   with	   0.01%	   EDTA	   to	   prevent	  coagulation.	   Centrifuged	   for	   20	   minutes	   at	   3000	   rpm.	   Plasma	   was	   added	   in	  volumes	  of	  200	  µl	  to	  which	  was	  added.	  	  
• Increasing	   concentrations	   of	   compound	  4	   (0.3	   ng	   to	   5ng)	   dissolved	   in	  acetone.	  
• The	  volume	  of	  plasma	  thus	  obtained	  was	  brought	  to	  800	  μl	  with	  acetone	  to	  precipitate	  all	  the	  plasma	  proteins.	  
• The	   samples	   was	   at	   4°C	   O/N	   for	   the	   separation	   of	   idrophilic	   and	  lypophile	  phases	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• The	  supernatant	  was	  transferred	  to	  new	  Eppendorf	  and	  evaporated	  by	  SpeedVac	  for	  1-­‐2	  hours.	  The	  residue	  was	  resuspended	  in	  50	  µl	  of	  solution	  B	  and	  100%	  of	  10	  µl	  injected	  in	  Mass.	  	  A	   second	  step	  of	   the	  pharmacokinetic	   study	  has	  been	   to	  build	   the	   regression	  line	  of	  the	  compound	  stocks-­‐58132	  as	  an	  internal	  standard.	  The	  construction	  of	  the	  line	  was	  made	  by	  injecting	  into	  the	  column	  increasing	  concentrations	  of	  the	  compound	  from	  0.315ng	  up	  to	  	  2ng.	  The	   regression	   line	   was	   then	   utilized	   to	   evaluate	   the	   performance	   of	   our	  method	  starting	  from	  mouse	  plasma	  samples	  with	  5ng	  of	  internal	  standard.	  An	  analysis	  carried	  out	  it	  was	  possible	  to	  calculate	  a	  yield	  of	  about	  30%	  (Figura	  7).	  	  
	  
Figure	  7:	  Linear	  regression	  analysis	  of	  the	  internal	  standard	  	  
y = 14911x 
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Later	  we	  assessed	  the	  concentration	  of	  the	  compound	  4	  present	  in	  the	  plasma	  of	  mice	   after	   i.p.	   administration	   at	   a	   concentration	   of	   50	  mg/kg/day.	   Taking	  into	  account	  the	  performance	  of	  our	  method	  of	  preparation	  we	  calculated	  that	  the	  plasma	  concentration	  of	  the	  compound	  4	  was	  1.4	  nM.	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Results	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Pharmacological	   evaluation	   of	   compounds	   identified	   by	   the	   virtual	  
screening	  approach.	  To	   induce	   Rac	   activation,	   human	   SMCs	   were	   starved	   for	   48h	   in	   DMEM	  containing	  0.4%	  FCS	  and	  then	  stimulated	  for	  2	  min	  with	  20	  ng/mL	  with	  PDGF-­‐BB.	   The	   effect	   of	   tested	   compounds	   was	   assessed	   by	   pre-­‐incubating	   human	  SMC	  for	  4h	  before	  stimulation.	  In	  the	  first	  series	  of	  G-­‐LISA	  assays,	  a	  final	  non-­‐toxic	   concentration	   (between	  10	  and	  200	  μM)	  of	   the	  57	   selected	   compounds	  was	   utilized,	   as	   determined	   by	  MTT	   cytotoxicity	   assay.	   Among	   the	   57	   tested	  compounds,	  23	  efficiently	  reduced	  the	  intracellular	  content	  of	  Rac-­‐GTP	  from	  a	  minimum	  of	  24.8%	  to	  a	  maximum	  of	  63.7%.	  Importantly,	  five	  compounds	  were	  shown	   to	  be	  more	  effective	   than	   the	   reference	   compound	  1	   and	   fifteen	  were	  more	   effective	   than	   compound	  2,	   indicating	   a	   potential	   improvement	   of	   the	  pharmacological	  inhibition	  of	  Rac	  by	  the	  newly	  identified	  chemical	  entities.	  	  A	  second	  series	  of	  analyses	  was	  performed	  at	  25	  μM	  concentration	  in	  order	  to	  select	  the	  most	  potent	  compounds	  (Figure	  8).	  	  
	  
Figure	  8:	  Inhibitory	  effect	  of	  the	  first	  12	  most	  potent	  compounds	  on	  Rac	  
activity.	  SMCs	  were	  incubated	  with	  selected	  compounds	  at	  final	  concentration	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Fig. 2  Selected regions of interest for chemical modification. 
 
 All the molecules with a TC value of ≥ 0.85 with respect to 
either compounds 1 (53 derivatives) and 2 (117 derivatives) were 5 
selected for molecular docking evaluation. As the receptor, the 
previously derived 3D model12 was used and a consensus docking 
strategy using two different software, MOE14 and Autodock4 
(AD4),15 and a total of three scoring functions (London dG and 
Affinity, implemented in MOE, and the default AD4 scoring 10 
function) was adopted as it proved to be a rather successful 
screening strategy.12 Energies obtained by MOE and AD4 virtual 
screenings were compared and only those compounds for which 
the computed docking energies resulted above defined thresholds 
(affinity < -4.5, London dG < -7.0, AD4 binding energy < -6.5 15 
kcal/mol) were selected. Within this selection, a total of 57 
commercially available -(sulfamoylaryl)arylamides with 
differences in regions 1 and 2 (Fig. 2) were selected and acquired 
for biochemical testing. 
 20 
Identification of new selective Rac inhibitors by in vitro and cell-
based assays. The pharmacological inhibition of the identified 
compounds on Rac activity was studied in cultured human SMCs 
by determining the amount of Rac-GTP by G-LISA assay.12  
 To induce Rac activation, human SMCs were starved for 48 h 25 
in DMEM containing 0.4 % of FCS and then stimulated for 2 min 
with 20 ng/mL platelet derived growth factor (PDGF)-BB. The 
effect of tested compounds was assessed by a 4 h pre-incubation 
of human SMC before stimulation. In a first series of G-LISA 
assays, a final non-toxic concentration of the 57 selected 30 
compounds was utilized, (between 10 and 200 µM) as determined 
by MTT cytotoxicity assay (data not shown). Among the 57 
tested compounds, 23 efficiently reduced the intracellular content 
of Rac-GTP from a minimum of 24.8 % to a maximum of 63.7 % 
(Table S1, ESI). Importantly, five compounds were shown to be 35 
more effective than the reference compound 1 and fifteen were 
more effective than compound 2, indicating a potential 
improvement of the pharmacological inhibition of Rac by the 
newly identified chemical entities. 
 A second series of analysis was performed at 25 µM 40 
concentration in order to select the most potent compounds. 
Compounds 3, 4, 5, 11 and 21 showed the most potent inhibitory 
action on Rac protein and consistently reduced, by more than 
50%, the intracellular amount of Rac-GTP (Table 1 and Table S2, 
ESI). A dose dependent effect on Rac activity showed that 45 
compounds 5 and 4 have the l west IC50 values, 4.4 µM and 8.7 
µM, respectively (Table 2, Fig. S1, ESI). 
 





cmpd R1 R2 R3 R4 R5 R6 X % inhibition at 25 µM 
21 H CH3 H CH3 CH3 H -CH2- 68.3±6.3 *** 
3 H CH3 H H H H -CH2- 67.4±1.5 *** 
11 H CH3 H H CH3 H -CH2- 65.3±9.0 *** 
4 H H H H H H -CH2- 61.1±3.0 *** 
5 H H H CH3 CH3 H -CH2- 59.3±1.2*** 
6 H H CH3 H H H -CH2- 51.9±3.1** 
10 H H CH3 CH3 CH3 H -CH2- 46.5±17.7 NS 
20 H H CH3 CH3 H CH3 -CH2- 45.5±24.2 * 
14 H H H CH3 CH3 H -CH2-CH2- 40.8±21.4* 
16 H H H H CH3 H -CH2-CH2- 26.1±3.8 *** 
24 H H CH3 H CH3 CH3 -CH2- 21.9±0.2 NS 
15 H H H H H H -CH2-CH2- NE 
NE: Not effective; NS: Not significant 
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of	   25	   μM	   for	   4	   hours	   and	   then	   Rac-­‐GTP	   levels	   was	   determined	  with	   G-­‐LISA	  assay.	  
	  	  Compounds	  3,	  4,	  5,	  11	  and	  21	  showed	  the	  most	  potent	  inhibitory	  action	  on	  Rac	  protein	  and	  consistently	  reduced,	  by	  more	  than	  50%,	  the	  intracellular	  amount	  of	  Rac-­‐GTP.	  A	  dose	  dependent	  effect	  on	  Rac	  activity	  showed	  that	  compounds	  5	  and	  4	  have	  the	  lowest	  IC50	  values,	  4.4	  μM	  and	  8.7	  μM,	  respectively214.	  In	  order	  to	  determine	  the	  selectivity	  of	  action	  of	  the	  tested	  compounds	  on	  Rac,	  the	  G-­‐LISA	  assay	  specific	  for	  RhoA	  was	  performed.	  	  
	  	  
Figure	  9:	   Effect	   of	   compound	  4	  on	  Rac	   and	  RhoA	  activity	   in	   SMCs.	  SMCs	  were	  incubated	  with	  selected	  compounds	  at	  final	  concentration	  of	  25	  μM	  for	  4	  hours	  and	  then	  Rho-­‐GTP	  levels	  was	  determined	  with	  G-­‐LISA	  assay.	  	  As	   shown	   in	   Figure	   9,	   compounds	   3,	   4,	   5,	   and	   21	   strongly	   reduced	   the	  intracellular	   levels	   of	   Rac-­‐GTP	   without	   significantly	   affecting	   the	   activity	   of	  RhoA,	  while	  compound	  11	  appears	  to	  be	  less	  Rac-­‐selective.	  	  
25μM%4 3 5 21 11 
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From	   the	   five	  most	   potent	   compounds	  we	   preformed	   a	   curve	   dose-­‐response	  and	  then	  calculated	  the	  IC50	  	  (Figure	  10).	  	  
	  
Figure	   10:	   Concentration-­‐dependent	   Rac	   inhibitory	   activity	   of	   selected	  
compounds.	   Rac1	   activity	   was	   determined	   after	   incubation	   with	   increasing	  concentrations	  of	  selected	  compounds	  and	  then	  evaluated	  by	  G-­‐LISA	  assay.	  IC50	  values	  were	  then	  calculated	  by	  using	  Sigma	  Plot	  software.	  	  In	   the	   table3	   we	   calculated	   the	   IC50	   of	   the	   five	   compounds,	   in	   particular,	  	  compounds	   4	   and	   5	   show	   an	   IC50	   lower	   than	   the	   starting	   compounds.	  Furthermore	   the	   compound	   4	   shows	   a	   modular	   dose	   response	   curve.	   Since	  compound	  4	  showed	  a	  good	  dose	  response	  curve	  and	  a	  good	  selectivity,	  it	  was	  considered	  the	  best	  candidate	  for	  further	  in	  vitro	  and	  in	  vivo	  studies.	  	  	  
Compound 4 
Compound 5 
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Table	  3:	  IC50	  values	  of	  selected	  compounds	  on	  Rac1	  inhibitory	  activity	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To	  investigate	  the	  basic	  molecular	  mechanism	  of	  Rac	  inhibition,	  we	  examined	  the	   effect	   of	   compound	  4	   on	   the	   exchange	   activity	   of	   Tiam1	   and	  TrioN,	   Rac-­‐specific	   GEFs215,216	   and	  Vav2,	   a	   GEF	   active	   on	  Rac1,	   RhoA,	   and	  Cdc42217.	   The	  treatment	  with	  compound	  4	  strongly	  reduced	  the	  Rac1-­‐GTP	  levels	  induced	  by	  SMCs	   expressing	   either	   Tiam1,	   TrioN,	   or	   Vav2214.	   These	   results	   indicate	   that	  compound	  4	  interferes	  with	  the	  GEF-­‐mediated	  Rac	  activation	  (Figure12).	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Figure	   13:	   Effect	   of	  downregulation	   by	   siRNA	   directed	   to	   Rac1	   on	   SMC	  
adhesion.	   Cells	   were	   seeded	   at	   a	   density	   of	   2x105/35	   mm	   petri	   dish	   and	  incubated	  with	  DMEM	  supplemented	  with	  10%	  FCS;	  24	  h	  later	  the	  cells	  were	  transfected	  with	  siRNA	  against	  Rac1	  or	  nonsilencing	  control	  siRNA	  scrambled.	  A)	   After	   24h	   SMCs	   were	   starved	   with	   medium	   containing	   0.4%	   FCS	   for	   an	  additional	  24h.	  At	   this	   time,	   the	  cells	  were	  harvested	  with	  Trypsin-­‐EDTA	  and	  cell	  adhesion	  on	  cultured	  petri	  dish	  evaluated.	  B)	  A	  parallel	  set	  of	  petri	  dishes	  were	   utilized	   for	   the	   determination	   of	   Rac1	   expression	   by	   western	   blot	  analysis	  with	  a	  monoclonal	  antibody	  anti	  Rac1	  (Clone	  23A8,	  Millipore).	  	  The	   effect	   of	   the	   five	   selected	   new	  Rac	   inhibitors	   on	   cell	   adhesion	  was	   then	  determined.	   SMCs	   were	   incubated	   for	   4	   h	   with	   increasing	   concentrations	   of	  compounds	   (10–50	   μM),	   harvested	   by	   trypsinization,	   and	   then	   cell	   adhesion	  was	  determined.	  All	  the	  compounds	  were	  capable	  of	  significantly	  affecting	  cell	  adhesion	   in	   a	   concentration-­‐dependent	   manner214	   (Figure14).	   In	   particular,	  compounds	  4,	  11	  and	  21	  showed	  very	  similar	  IC50	  values	  on	  the	  cell	  adhesion	  and	   the	   inhibitory	   action	   on	   Rac,	   demonstrating	   the	   effective	   inhibition	   of	   a	  Rac-­‐mediated	  cellular	  event	  by	  these	  compounds.	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Figure15:	   Effect	   of	   compound	   4	   on	   SMC	  migration	   assessed	   by	   Boyden	  
chamber.	   The	   cells	   were	   seeded	   on	   top	   of	   the	   chamber	   in	   the	   presence	   or	  absence	  of	  compound	  4	  at	  increasing	  concentrations.	  As	  stimulus	  mitogen	  was	  added	  at	  the	  lower	  part	  of	  the	  chamber	  of	  20ng/ml	  PDGF-­‐BB.	  After	  6	  hours	  of	  migration	  membrane	  was	  fixed,	  stained	  cells	  and	  their	  number	  determined	  in	  the	  microscope	  with	  a	  magnification	  of	  10X.	  	  As	  shown	  in	  Figure	  15,	  compound	  4	  significantly	  inhibited	  cell	  migration	  in	  a	  concentration-­‐dependent	   manner	   with	   a	   calculated	   IC50	   value	   of	   8.8	   µM	  (Figure15).	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containing	  0.4%	  FCS,	   and	   the	   cultures	  were	   incubated	   for	   48	  h.	  At	   this	   time,	  compound	  13	  was	  added	  to	  the	  cultured	  media	  at	  the	  final	  concentration	  of	  10	  µM	  in	  the	  presence	  of	  PDGF-­‐BB	  (10	  ng/ml).	  Cell	  movement	  was	  determined	  by	  video	  microscopy	  analysis	  and	  the	  distance	  covered	  by	  10	  different	  cells	  in	  16	  h	  was	  measured	  for	  each	  condition.	  The	  data	  are	  expressed	  as	  mean	  ±	  SD.	  	  To	   confirm	   that	   compound	  4	   inhibits	   cell	  migration,	  we	   performed	   a	   second	  experiment	   on	   cell	   motility	   by	   video	   microscopy	   analysis	   conducted	   in	   the	  presence	   of	   PDGF-­‐BB	   for	   16hrs	   (Figure16).	   Under	   these	   experimental	  conditions	  compound	  4	  significantly	  affected	  cell	  motility	  with	  an	  IC50	  value	  of	  1.75	  µM.	  Finally,	  compound	  4	  was	  shown	  to	   inhibit	   lamellipodia	  formation	  in	  human	   SMCs	   induced	   by	   PDGF-­‐BB	   (Figure17),	   a	   cellular	   response	   strikingly	  related	  to	  Rac1	  activity214.	  
	  
Figure17:	  Effect	  of	   compound	  4	  on	  cytoskeleton	  organization.	  Cells	  were	  incubated	  with	  Compound	  4	   at	   the	   final	   concentration	  of	   10μM	  and	  after	  4h	  SMCs	  were	   stimulated	  by	   adding	  PDGF-­‐BB	   (10	  ng/ml)	   for	   10min.	   Cells	  were	  then	   fixed	   in	   4%	   paraformaldehyde	   and	   labeled	   with	   FITC-­‐phalloidin	   and	  analyzed	  by	  fluorescent	  microscope.	  	  	  
Basal PDGF Compound 4 1µM 
Compound 4 2,5µM Compound 4 5µM  Compound 4 10µM 
	   81	  
	  
Figure18:	  Effect	  of	  compound	  4	  on	  ROS	  production	  in	  human	  monocytes.	  To	   evaluate	   superoxide	   anion	   (O2-­‐)	   production,	   monocytes	   (1	   x	   106	   cells/	  plate)	  were	   first	   treated	   for	   1	   h	  with	   compound	   4	   and	   then	   stimulated	  with	  PMA	   10-­‐7	   M	   for	   30	   min.	   O2-­‐	   production	   was	   evaluated	   by	   the	   superoxide	  dismutase	   (SOD)-­‐inhibitable	   cytochrome	  C	   reduction	   assay	   and	   expressed	   as	  value	   of	   PMA-­‐induced	   ROS	   production	   inhibition.	   The	   absorbance	   changes	  were	  recorded	  at	  550	  nm	  in	  a	  Beckman	  DU	  650	  spectrophotometer.	  To	  avoid	  interference	   with	   spectrophotometrical	   recordings	   of	   O2-­‐	   production,	   cells	  were	  incubated	  with	  RPMI	  1640	  without	  phenol	  red,	  antibiotics	  and	  FBS.	  	  	  Rac1	   is	   very	   important	   for	   the	   activation	   of	   NADPH	   oxidase	   and	   thus	   has	   a	  pivotal	  role	   in	  the	  production	  of	  ROS.	  With	  the	  cytochrome	  C	  reduction	  assay	  we	   evaluated	   the	   effects	   of	   compound	  4	   on	   superoxide	   anion	   production	   in	  human	   monocytes.	   Compound	   4	   significantly	   inhibited	   the	   ROS	   production	  with	   an	   IC50	   of	   1nM	   (Figure	   18).	   These	   results	   further	   demonstrate	   that	  compound	  4	  inhibits	  Rac	  activity	  eliciting	  a	  potential	  antioxidant	  activity.	  	  
ROS production inhibition in monocytes
n=4
Method
To evaluate superoxide anion (O2-) production, 
monocytes (1 x 106 cells/ plate) were first treated 
for 1 h with Rac1 inhibitor (referred as “composto
4”) and then stimulated with PMA 10-7 M for 30 min. 
O2- production was evaluated by the superoxide 
dismutase (SOD)-inhibitable cytochrome C 
reduction assay and expressed as value of PMA-
induced ROS production inhibition. The absorbance 
changes were recorded at 550 nm in a Beckman 
DU 650 spectrophotometer. To avoid interference 
with spectrophotometrical recordings of O2-
production, cells were incubated with RPMI 1640 
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Pharmacological	   evaluation	   of	   arylsubstituted	   2-­‐amino-­‐3-­‐
(phenylsulfanyl)norbornane-­‐2-­‐carboxylates	  on	  Rac1	  activity.	  	  The	  second	  series	  of	  compounds	  with	  potential	  Rac	  inhibitory	  activity	  derived	  by	  a	  different	  approach	  (see	  material	  and	  methos)	  were	  tested	  under	  the	  same	  experimental	  conditions	  reported	  for	  the	  previous	  series.	  As	  shown	  in	  (Figure	  19),	  all	  the	  compounds	  significantly	  reduced	  the	  intracellular	  levels	  of	  Rac-­‐GTP	  at	   10µM	   concentration,	   and	   compound	  13	   reduced	   the	   levels	   of	   Rac-­‐GTP	   by	  75%	   compared	   to	   control	   cells210.	   At	   the	   same	   concentration,	   the	   compound	  did	   not	   interfere	   with	   RhoA	   activation,	   demonstrating	   a	   selective	   action	  towards	   Rac	   protein,	   moreover	   compound	   13	   affects	   cell	   migration	   and	  motility	  capacity	  in	  response	  to	  the	  chemotactic	  response	  to	  PDGF-­‐BB.	  
	  
Figure	  19:	  Effect	  of	  newly	  synthesized	  compounds	  on	  Rac-­‐GTP	  and	  RhoA-­‐
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protein	   extracts	   and	   G-­‐LISA	   assays	   were	   then	   performed.	   The	   data	   are	  expressed	  as	  mean	  ±	  SD	  of	  triplicates.	  	  In	   particular,	   compound	   13,	   selectively	   reduced	   the	   Rac-­‐GTP	   levels	   in	   a	  concentration	  dependent-­‐manner	  with	  an	  IC50	  value	  of	  2.5	  µM	  with	  no	  effect	  on	  RhoA	  (Figure	  20).	  	  	  
	  
Figure	   20:	   Effect	   of	   compound	   13	   on	   Rac-­‐GTP	   and	   RhoA-­‐GTP	   levels	   in	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Figure	  21:	  Effect	  of	  compound	  13	  on	  SMC	  migration	  in	  response	  to	  PDGF-­‐
BB.	   	  SMCs	  were	  seeded	  at	  a	  density	  of	  2x105/35	  mm	  petri	  dish	  and	  incubated	  with	  DMEM	  supplemented	  with	  10%	  FCS;	  24h	  later	  the	  medium	  was	  changed	  to	  one	  containing	  0.4%	  FCS,	  and	   the	  cultures	  were	   incubated	   for	  48h.	  At	   this	  time,	   compound	   13	   was	   added	   to	   the	   cultured	   media	   at	   the	   indicated	   final	  concentrations.	  After	  4h	  of	   incubation	  cells	  were	  harvested	  with	   trypsin,	   and	  cell	  migration	  determined	  by	   the	  Boyden	  chamber	  chemotaxis	  assay	   towards	  PDGF-­‐BB	  (20	  ng/ml).	  The	  number	  of	  transmigrated	  cells	  was	  counted	  in	  three	  random	  high-­‐power	   fields	  under	  high	  magnification	  (×20	  objective	   lens).	  The	  data	  are	  expressed	  as	  mean	  ±	  SD	  of	  triplicates.	  	  The	   effect	   of	   compound	   13	   was	   also	   assessed	   on	   the	   mobility	   of	   SMCs	   by	  monitoring	   with	   a	   video	   microscopy	   (Figure	   22).	   During	   the	   16	   h	   of	   video	  microscopy	  analysis,	  PDGF	  increased	  by	  approximately	  2	  fold	  the	  cell	  motility	  and	  this	  response	  was	  completely	  abrogated	  by	  the	  incubation	  with	  compound	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Figure	   22:	   Effect	   of	   compound	  13	   on	   SMC	  motility	   in	   response	   to	  PDGF-­‐BB.	  SMCs	  were	   seeded	   at	   a	   density	   of	   2x104	   of	   24	  well	   tray	   and	   incubated	  with	  DMEM	  supplemented	  with	  10%	  FCS;	  24h	  later	  the	  medium	  was	  changed	  to	  one	  containing	  0.4%	  FCS,	   and	   the	   cultures	  were	   incubated	   for	   48	  h.	  At	   this	   time,	  compound	  13	  was	  added	  to	  the	  cultured	  media	  at	  the	  final	  concentration	  of	  10	  µM	  in	  the	  presence	  of	  PDGF-­‐BB	  (10	  ng/ml).	  Cell	  movement	  was	  determined	  by	  video	  microscopy	  analysis	  and	  the	  distance	  covered	  by	  10	  different	  cells	  in	  16	  h	  was	  measured	  for	  each	  condition.	  The	  data	  are	  expressed	  as	  mean	  ±	  SD.	  	  Taken	   together	   the	   compound	   13	   was	   shown	   to	   selectively	   reduced	   the	  intracellular	   levels	  of	  Rac-­‐GTP	  and	   the	  cell	  migration,	  an	  event	  dependent	  by	  its	  activity210.	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In	  vivo	  pharmacokinetic	  and	  pharmacodynamic	  study	  in	  C57	  BL/6	  mice.	  	  Once	  identified	  in	  compound	  4	  the	  best	  candidate	  for	  the	  in	  vivo	  evaluation	  on	  cardiac	  hypertrophy	  and	  atherosclerosis,	   in	  a	   first	  series	  of	  experiments	  both	  the	  pharmacokinetic	  and	  the	  pharmacodynamics	  profile	  were	  determined.	  For	  these	  analysis	  compound	  4	  was	  administered	  in	  C57BL/6	  mice	  at	  a	  dose	  of	  50	  and	  100	  mg/kg/day	  (i.p.	  injection	  of	  CMC	  suspension)	  for	  three	  days	  and	  after	  the	  last	  injection	  both	  the	  plasma	  levels	  of	  compound	  4	  and	  the	  cardiac	  levels	  of	  Rac-­‐GTP	  were	  determined.	  After	  the	  last	  administration	  the	  compound	  at	  a	  dosage	  of	  50	  mg/kg/day	  it	  was	  observed	   a	   35%	   reduction	   of	   Rac-­‐GTP	   levels	   in	   cardiac	   homogenates	   at	   1h	  together	  with	   	   a	   Cmax	   of	   925	   ng/ml	   ,	   while	   at	   a	   dose	   of	   100mg/kg/day	  we	  observed	  a	  Cmax	  of	  2050	  ng/ml	  after	  3h	  with	  a	  reduction	  of	  98%	  of	  Rac-­‐GTP	  (Figure	  21	  and	  22).	  	  	  
	  
Figure	   21.	   Experimental	   protocol	   for	   pharmacokinetic	   and	  
pharmacodynamic	  studies.	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Figure	   23:	   Plasma	   levels	   of	   compound	   4.	   Compound	  4	   was	   administered	  every	   24h	   for	   3	   days	   by	   i.p.	   at	   50	   and	   100mg/kg	   per	   day.	   The	   Compound	  4	  levels	   in	  plasma	  were	  evaluated	  by	  HPLC-­‐MS	  after	  1,	  3	  and	  6	  hours	   from	  last	  administration.	  	  	  
	  
Figure24:	   Rac1-­‐GTP	   levels	   in	   mouse	   heart	   after	   compound	   4	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Moreover,	   the	  pharmacokinetic	  analysis	  clearly	  showed	  that	   the	  compound	  4	  does	  not	  accumulate	  in	  the	  body	  but	  is	  rapidly	  excreted	  (Figure23).	  
	  
Characterization	  of	  heart	  hypertrophy	  model.	  Before	  starting	  with	  the	  in	  vivo	  study	  of	  compound	  4	  we	  characterized	  a	  mouse	  model	   of	   heart	   hypertrophy	   induced	   by	   infusion	   of	   Angiotensin	   II	   through	  osmotic	  pump	  (alzet	  1004)	  at	  a	  concentration	  of	  1000	  and	  2000mg/kg/min.	  We	   treated	   the	  mice	   for	  2	  weeks	  with	  Angiotensin	   II	   and,	   at	   the	   end	  of	   each	  week,	  we	  monitored	  by	  MRI	   the	  volume	  of	  Left	   ventricle,	   fraction	  of	   ejection	  and	  collected	  plasma	  to	  measure	  the	  concentration	  of	  AngII	  in	  plasma.	  	  
	  
Figure	   25:	   Experimental	   protocol	   of	   heart	   hypertrophy	   induced	   by	  
angiotensin-­‐II	  infusion.	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Figure	  26:	  MRI	  images	  of	  short	  axis	  view	  in	  C57BL/6	  mice	  after	  infusion	  
of	  angiotensin	  II	  with	  osmotic	  pumps.	  	  
	  In	  figure	  26	  we	  can	  observe	  in	  mice	  treated	  for	  14	  weeks	  with	  angiotensin	  II	  a	  development	   of	   a	   dilation	   of	   left	   ventriculum	   during	   the	   end-­‐diastole	   and	  systolic	  phases.	  	  	  
	  

















Physiologic Ang-II (2000 ng/Kg per min) 
Day 14 after implantation of osmotic pumps 
!me$point$ EDV$(µl)$ ESV$(µl)$ EF$(%)$ SV$(µl)$
Control$ pre$ 60,7$ 18,25$ 70,09$ 42,55$
2weeks$ 59,85$ 18,05$ 69,7075$ 41,8$
Ang$II$ pre$ 59,6$ 21,15$ 65,005$ 38,5$
2weeks$ 67,1% 29,35% 56,175% 37,75%
EDV: end diastolic volume 
ESV: end-systolic volume 
EF: ejection fraction 
SV: stroke volume 
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In	  table	  4	  we	  observe	  that	  angiotensin	  infusion	  determines	  an	  increase	  of	  end	  diastolic	   and	   end	   systolic	   volume	   and	   a	   reduction	   of	   ejection	   fraction	   and	  stroke	  volume.	  These	  parameters	  indicate	  an	  induction	  of	  heart	  hypertrophy.	  At	   the	  end	  of	   the	   treatment	   the	  animals	  were	   sacrified	  and	  heart	   tissues	  and	  plasma	  were	  collected.	  From	  the	  heart	  tissues	  we	  performed	  a	  quantitative	  RT-­‐PCR	  analysis	  to	  see	  the	  gene	  expression	  of	  cardiac	  fetal	  gene,	  in	  particular	  ANF,	  BNP	  and	  skeletal	  muscle	  action	  (SMA),	  the	  well	  established	  surrogate	  markers	  of	  cardiac	  hypertrophy.	  
	   	  
Figure	  27:	  mRNA	  levels	  of	  ANF,	  BNP,	  and	  SMA	  in	  the	  heart	  of	  control	  and	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BNP	   and	   ten	   times	   for	   SMA	   while	   at	   a	   dose	   of	   2000mg/kg/day	   there	   is	   an	  increase	  of	  three	  times	  for	  ANF,	  two	  times	  for	  BNP	  and	  four	  times	  for	  SMA.	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Evaluation	   of	   the	   effects	   of	   compound	   4	   in	   heart	   hypertrophy	   mouse	  
model.	  	  Once	   characterized	   model	   of	   cardiac	   hypertrophy	   in	   mice	   C57	   BL/6,	   we	  repeated	   the	   experiment	   treating	   the	  mice	  with	   compound	  4	   for	   two	  weeks	  and	   then	   performed	   a	   quantitative	   RT-­‐PCR	   to	   evaluate	   the	   expression	   of	  cardiac	  fetal	  genes	  ANF,	  BNP	  and	  SMA.	   	  
	  	  
Figure	  28:	  mRNA	  levels	  of	  ANF,	  BNP,	  and	  SMA	  in	  the	  hearts	  of	  angiotensin	  
II	   compared	   to	   angiotensin	   II	  with	   compound	  4	  mice.	  Angiotensin	   II	  was	  infused	  in	  C57BL/6	  mice	  by	  using	  osmotic	  pumps	  Alzet	  (mod.1004)	  at	  the	  rate	  of	   2000	   mg/kg/day.	   For	   the	   treated	   mice	   we	   administered	   every	   day	  75mg/kg/day	   of	   compound	   4.	   After	   2	   weeks	   of	   treatment	   the	   mice	   were	  sacrificed,	   and	   heart	   phenotipic	   marker	   levels	   determined	   by	   RT-­‐PCR	   from	  total	  RNA	  of	  cardiac	  tissue.	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These	  results	  seem	  to	  confirm	  that	  the	  inhibition	  of	  Rac	  through	  compound	  4	  may	  have	  cardioprotective	  effects.	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Discussion	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In	   the	  present	  study	   it	  has	  been	  utilized	   two	  different	  approaches	   to	  develop	  new	  Rac	  inhibitors:	  a	  virtual	  screening	  and	  a	  computer	  aided	  de-­‐novo	  design	  of	  a	  new	  scaffold,	  starting	  from	  the	  previously	  described	  3D	  model	  of	  the	  complex	  between	  Rac1	  and	  NSC23766.	  	  In	  the	  first	  approach,	  we	  started	  from	  previously	   identified	  hits207,	  by	  using	  a	  virtual	   screening	   approach	   we	   identified	   a	   series	   of	   3-­‐aryl-­‐N-­‐aminoylsulfonylphenyl-­‐1H-­‐pyrazole-­‐5-­‐carboxamides	   as	   potent	   and	   selective	  Rac	   inhibitors.	   In	   particular,	   compounds	   4	   and	   5	   selectively	   inhibited	   Rac	  activity	  with	   IC50	   values	   lower	   than	   the	  previously	   reported	   compounds	   (8.7	  µM	  and	  4.4	  µM	  compared	  to	  12.2	  µM	  and	  24.1	  µM,	  respectively)207.	  The	  effect	  of	   the	  new	  compounds	  was	   then	   studied	  on	   cell	   adhesion,	   a	   cell-­‐based	  assay	  directly	  linked	  to	  Rac	  activity.	  These	  set	  of	  experiments	  were	  considered	  more	  indicative	   of	   the	   effect	   of	   the	   new	   compounds	   on	   Rac	   functionality	   than	   the	  determination	  of	   the	   intracellular	   levels	  of	  Rac-­‐GTP	   levels.	  The	  results	  of	   this	  analysis	  confirmed	  that	  all	  the	  compounds	  inhibited	  the	  cell	  adhesion	  with	  IC50	  values	   similar	   to	   those	   observed	   by	   G-­‐LISA	   assay.	   This	   observation	  demonstrated	   a	   direct	   relationship	   between	   the	   levels	   of	   Rac-­‐GTP	   and	   its	  action	  on	  cell	  adhesion.	  In	  particular,	  compound	  4	  was	  the	  second	  most	  potent	  compound	  and	  inhibited	  the	  cell	  adhesion	  with	  an	  IC50	  of	  8.7	  µM	  equal	  to	  that	  observed	   by	   G-­‐LISA	   assay.	   Compound	   4	   completely	   inhibited	   lamellipodia	  formation	   in	   response	   to	   PDGF,	   a	   Rac1-­‐dependent	   cellular	   effect,	   further	  confirming	  its	  inhibitory	  action	  on	  Rac	  functionality.	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Other	  small	  molecules	  with	  Rac1	  inhibitory	  activity	  have	  been	  described	  after	  the	   first	   discovered	   compound	   NSC23766,	   with	   some	   differences	   in	   their	  mechanisms	   of	   action.	   Compounds	   4	   and	   5	   appear	   to	   act,	   similarly	   to	  NSC23766,	   by	   interfering	   with	   the	   Rac1–Tiam1	   interaction.	   The	   same	   effect	  was	  shown	  for	  NSC23766	  which	  also	  interferes	  with	  the	  Rac1–TrioN	  binding,	  while	   the	   effect	   on	   Vav2,	   another	   GEF	   capable	   of	   activating	   Rac,	   was	   not	  assessed155.	   Compound	   4	   described	   in	   the	   present	   research	   program	   was	  shown	  to	  affect	  the	  Rac	  activity	  induced	  by	  three	  different	  GEFs,	  Tiam1,	  TrioN,	  or	   Vav2,	   and	   thus	   with	   a	   similar	   mechanism	   of	   action	   as	   demonstrated	   for	  compounds	   4,	   5	   and	   NSC23766.	   A	   more	   specific	   inhibitory	   action	   was	   then	  observed	  for	  the	  compound	  ITX3	  which	  interferes	  with	  Trio	  without	  affecting	  the	   activation	   of	   Rac	   and	   RhoG	   by	   both	   Tiam1	   and	   Vav2156.	   In	   contrast,	  compound	   EHop-­‐016,	   another	   previously	   described	   potent	   Rac	   inhibitor,	  affects	  Vav2-­‐mediated	  GDP–GTP	  exchange	  of	  Rac	  and	  shows	  a	   ten-­‐fold	   lower	  affinity	  for	  Tiam1	  and	  probably	  no	  effect	  on	  Trio219.	  While	  Vav2	  is	  a	  GEF	  active	  on	  Rac1,	  RhoA,	  and	  Cdc42,	  compound	  EHop-­‐016	  was	  shown	  to	   interfere	  only	  with	   Rac–Vav2	   interaction,	   a	   selective	   effect	   potentially	   responsible	   for	   the	  observed	  increased	  RhoA	  activation	  in	  cancer	  cells	  for	  the	  higher	  availability	  of	  Vav2220.	   Interestingly,	   compound	  4	   has	   shown	   a	   trend	   of	   induction	   of	   RhoA	  activity,	   although	   not	   statistically	   significant,	   suggesting	   a	   similar	  compensatory	   effect	   to	   that	   observed	   for	   compound	   EHop-­‐016.	   A	   third	  chemical	   entity,	   compound	   EHT	   1864,	   has	   been	   discovered	   to	   selectively	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inhibit	   Rac	   without	   interfering	   with	   the	   binding	   between	   Rac	   and	   GEF221.	  Although	  the	  mechanism	  of	  action	  has	  not	  yet	  been	  resolved,	  from	  the	  obtained	  data	  a	  possible	  allosteric	  mechanism	  has	  been	  suggested	  for	  the	  loss	  of	  binding	  with	   nucleotide.	   In	   conclusion,	   through	   a	   computational	   approach	   we	  identified	   a	  new	  class	  of	  Rac	   inhibitors	   that	  potently	   and	   selectively	   reduced	  the	  intracellular	  levels	  of	  Rac-­‐GTP	  and	  its	  activity,	  demonstrated	  by	  effects	  on	  the	  lamellipodia	  formation,	  cell	  adhesion,	  migration	  and	  a	  powerfull	  reduction	  of	  superoxide	  anion	  production	  (IC50	  1nM)	  in	  human	  monocytes	  showing	  how	  by	   inhibiting	   Rac	   we	   obtain	   a	   significantly	   antioxidant	   effect.	   These	   effects	  appear	  to	  be	  related	  to	  the	  inhibition	  of	  GEF-­‐mediated	  GTP–GDP	  exchange	  on	  Rac,	  since	  compound	  4	  affected	  Rac	  activation	  induced	  by	  either	  Tiam1,	  TrioN	  or	  Vav2,	   implying	   a	   selective	   interference	  of	  Rac1–GEF	   interaction	   similar	   to	  that	  described	  for	  compound	  NSC23766.	  	  Since	   this	   compound	   appeared	   to	   be	   suitable	   for	   investigating	   its	   effect	   on	  cardiac	   hypertrophy	   and/or	   atherosclerotic	   plaque	   formation	   in	   in	   vivo	  experimental	   models,	   we	   begun	   to	   characterize	   an	   in	   vivo	   model	   to	   cardiac	  hypertrophy	   and	   to	   evaluate	   the	   pharmacokinetic	   and	   pharmacodinamic	  profile	  of	  Compound	  4.	  	  From	  these	  analysis	  we	  observed	  a	  dose-­‐dependent	  effect	  of	   compound	  4	   on	  Rac1-­‐GTP	   levels	   in	   the	   heart	   of	   mice	   after	   i.p.	   injection.	   In	   particular	   at	  concentration	  of	  100mg/kg	  per	  day	  a	  very	  significant	  reduction	  of	  95%	  of	  Rac-­‐GTP	   levels	   was	   achieved,	   together	   with	   a	   Cmax	   at	   a	   concentration	  approximately	  equal	   to	  5µM.	  However,	  Rac1	   is	   expressed	  ubiquitously	   in	   the	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body	  and	  this	  powerfull	  inhibition	  caused	  also	  an	  important	  adverse	  effect	  as	  a	  complete	   intestinal	   blockage,	   suggesting	   that	   in	   a	   future	   study	   a	   lower	   dose	  should	  be	  used.	  Another	   approach	  used	   to	   identify	  new	  Rac	   inhibitors	  was	  a	   computer	   aided	  
de-­‐novo	   design	   of	   a	   new	   scaffold,	   starting	   from	   the	   previously	   described	   3D	  model	   of	   the	   complex	   between	  Rac1	   and	  NSC23766.	   This	   analysis	   led	   to	   the	  synthesis	   of	   the	   derivatives	   of	   arylsubstituted	   2-­‐amino-­‐3-­‐(phenylsulfanyl)norbornane-­‐2-­‐carboxylate	   as	   new	   potential	   class	   of	   Rac	  inhibitors.	  This	  class	  of	  compounds	  further	  improves	  both	  the	  potency	  and	  the	  effectiveness	   of	   the	   Rac1	   inhibitory	   activity	   with	   IC50	   value	   of	   2.5	   µM	   and	   a	  75%	   reduction	   of	   Rac-­‐GTP	   intracellular	   levels.	   In	   addition,	   these	   compounds	  resulted	  also	  selective	  for	  Rac1	  without	  affecting	  the	  RhoA	  activity.	  In	   the	   future	   the	  efficacy	  on	  heart	  hypertrophy	  of	  both	  classes	  of	  compounds	  will	  be	  tested	  by	  using	  the	  cardiac	  hypertrophy	  model	  characterized	  within	  the	  present	   work	   in	   order	   to	   establish	   the	   role	   of	   Rac	   on	   this	   disease	   and	   the	  suitability	  of	  a	  pharmacological	  intervention.	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